Document:

Processing and Supply Agreement

 
 Confidential Treatment Requested 
 
  
 Exhibit 10.57 
  
 PROCESSING AND SUPPLY
AGREEMENT—NatrecorR BNP 
 between 
 ABBOTT LABORATORIES and SCIOS INC. 
  

This Agreement is made effective as of December 1, 1997 (the “Effective Date”), by and between SCIOS INC., a Delaware corporation having its principal place
of business at 2450 Bayshore Parkway, Mountain View, California 94043 (“Scios”), and ABBOTT LABORATORIES, an Illinois corporation having its principal place of business at 100 Abbott Park Road, Abbott Park, Illinois 60064-3500
(“Abbott”). 
  
 BACKGROUND 
  
 A.    Abbott represents to Scios that its manufacturing facility in McPherson, Kansas doing business as Abbott Laboratories-McPherson has experience,
suitable facilities and the capability to compound, fill and finish, and test pharmaceutical compounds, and experience in the commercial manufacture of pharmaceutical compounds according to current good manufacturing practices (cGMP) and other
applicable requirements. 
  
 B.    Scios desires to have Abbott undertake, using bulk material
supplied by Scios, the preparation of finished vials of NatrecorR BNP (“BNP”) for use in
clinical trials and subsequent commercialization if the product is approved for marketing by the appropriate regulatory authorities. 
  
 C.    Abbott desires to perform the services specified in this Agreement, both during Scios’ clinical trials of BNP and subsequent commercialization if the product is approved for marketing by the
appropriate regulatory authorities. 
  
 NOW, THEREFORE, in consideration of the mutual promises and covenants set forth herein, the
parties agree as follows: 
  
 Section 1.—Definitions 
  
 The following terms shall have the indicated meanings for purposes of this Agreement: 
  
 1.1    “Affiliate” of a party hereto means an entity which controls, is controlled by,
or is under common control with such party. For purposes of this definition, an entity shall be deemed to control another entity if it owns or controls, directly or indirectly, at least fifty percent (50%) of the voting equity of such other entity
(or other comparable ownership interest for any entity other than a corporation). 
  
 1.2    “BNP” means the pharmacologically active compound known as NatrecorR BNP, a form of b-type natriuretic peptide. 
  
 1.3    “Bulk BNP” means BNP in bulk form meeting the Specifications listed in Exhibit B to be supplied by Scios to Abbott. 
 
 *****    Confidential portions of this material have been omitted and filed separately with the Securities and Exchange Commission. 

 
 1 

 
 Confidential Treatment Requested 
 
  
 1.4    “Scios Know-How” means all know-how, inventions, technical and other information and data supplied by Scios to
Abbott in connection with the work, including, without limitation, design and manufacturing drawings or sketches; formulae; compositions; processes and procedures; apparatus; correlation data; flow sheets; reports; operating, test and performance
data; and process, mechanical, material and product specifications related to the production of Product, including any patents or know-how acquired or licensed by Scios from a third party, to the extent Scios is permitted to grant a license to
Abbott in such third party technology. 
  
 1.5    “Scios Patents”
means Scios’ patents in all countries, including improvement patents, patents of addition, patents of importation, certificates of invention, utility model and design patents, and all reissues, renewals and extensions thereof; and applications
for such patents, including original, divisional, continuation and continuation-in-part applications pending before any patent office related to the production of Product. 
  
 1.6    “Containers and Packaging” means the containers and closures and the packaging and labeling used in the
manufacture and shipping of Product pursuant to the Specifications. 
  
 1.7    “Data” means all books, records, batch records, reports, lab notebooks, charts, graphs, comments, computations, analyses, recordings, photographs, computer programs and
documentation thereof, computer information storage means, sample of materials and other graphic or written data which relate to the Manufacturing and Testing of the Product pursuant to this Agreement, including any data required to be maintained
pursuant to applicable FDA or other governmental regulations. 
  
 1.8    “FDA” means the United States Food and Drug Administration. 
  
 1.9    “Fill and Finish Program” or “Fill and Finish Work” means the manufacture (including all processes necessary to supply Product), testing, packaging,
labeling and delivery of Product pursuant to the Specifications described in Exhibit B and cGMP standards. 
  
 1.10    “Abbott Know-How” means all of Abbott’s inventions, technical and other information and data, including, without limitation, design and manufacturing drawings or
sketches; formulae; compositions; processes and procedures; apparatus; correlation data; flow sheets; reports; operating, test and performance data; and process, mechanical, material and product specifications directly related to the production of
Product including any patents or know-how acquired or licensed by Abbott from a third party, to the extent Abbott is permitted to grant a license to Scios in such third party technology. 
  
 1.11    “Abbott Patents” means Abbott’s patents in all countries, including improvement patents, patents of
addition, patents of importation, certificates of invention, utility model and design patents, and all reissues, renewals and extensions thereof; and applications for such patents, including original, divisional, continuation and
continuation-in-part applications pending before any patent office related to the production of Product. 
 
 *****    Confidential portions of this
material have been omitted and filed separately with the Securities and Exchange Commission. 

 
 2 

 
 Confidential Treatment Requested 
 
  
 1.12    “Master Production and Control Records” means the records and data to be generated in the Manufacturing and
Testing of Product by Abbott to demonstrate that all applicable standard operating procedures and methods have been followed as specified in Exhibit B and Exhibit C and such modifications or changes thereto specified by Scios and Abbott pursuant to
Section 2.5 and otherwise satisfy cGMP standards. Master Production and Control Records shall not include the operating procedures and related data of Abbott that are produced in connection with its general operations. 
  
 1.13    “NDA” means a New Drug Application or other equivalent application seeking
approval to market Product, and any supplement or amendment relating thereto, filed with the FDA by or on behalf of Scios or any licensee or commercial partner of Scios. 
  
 1.14    “Placebo” means the form of Product meeting the Specifications respectively described in Exhibit B that lacks
BNP. 
  
 1.15    “Final Product” means the form of Product meeting
the Specifications respectively described in Exhibit B that contains BNP. 
  
 1.16    “Product” means both Final Product and/or Placebo meeting the respective Specifications set forth in Exhibit B. 
  
 1.17    “Raw Materials” shall mean all components of Product excluding Bulk BNP and Containers and Packaging, all of
which shall meet the Specifications for Raw Materials. 
  
 1.18    “Regulatory
Approval” or words of similar import means approval by the FDA of Scios’ NDA or other marketing application for Products for the first indication. 
  
 1.19    “Specifications” means the specifications for each of BNP, Bulk BNP, Containers and Packaging, Raw Materials and
Product as established by Scios in Exhibit B and such modifications or changes thereto specified by Scios pursuant to Section 2.5. 
  
 1.20    “Processing Order” or “Purchase Order” means an instruction submitted in writing to Abbott by Scios requesting Abbott to perform Fill and Finish Work for a
specified quantity of Product for delivery upon specified terms. Such Processing Order will be in substantially the form of Exhibit A, and shall be in compliance with this Agreement. 
  
 1.21    “cGMP” means current Good Manufacturing Practices under 21 C.F.R. Parts 200 and 211. 
  
 Section 2.—Fill and Finish Program 
  
 2.1    Supply. 
  
 2.1.1    General.    Abbott agrees to perform Fill and Finish Work as requested by Scios or a third party licensee or partner designated by Scios from time to time pursuant to
this 
 
 *****    Confidential portions of this material have been omitted and filed separately with the Securities and Exchange Commission.

 
 3 

 
 Confidential Treatment Requested 
 
  
 Agreement. Subject to the other provisions set forth below, Abbott shall provide such facilities, equipment and services as may be required to perform Fill and Finish Work
of Product under this Agreement. In preparing Product, Abbott shall adhere to (a) the compounding, processing, lyophilization, manufacturing, testing and control procedures as set forth in Exhibit C (as modified pursuant to Section 2.2 to reflect
the size of each batch requested by a Processing Order), (b) information provided by Scios and agreed to in writing by Abbott and (c) cGMP standards.’ 
  
 2.1.2    Requirements.    For orders placed before the first anniversary of the date that the FDA
approves the first Final Product for sale in the United States, Scios agrees to purchase, and Abbott agrees to supply, 100% of Scios’ requirements for the fill and finish of Final Product that is intended for distribution in the United States.
For orders placed between the first anniversary and the second anniversary of FDA approval of the first Final Product, Scios agrees to purchase, and Abbott agrees to supply, 50% of Scios’ requirements for the fill and finish of Final Product
that is intended for distribution in the United States. After the second anniversary of FDA approval of the first Final Product, Scios may source fill and finish services from Abbott or another vendor as Scios elects. If at anytime prior to the
second anniversary of FDA approval of the first Final Product, Abbott is unable to fulfill Scios’ requirements as stated above either from Abbott’s McPherson facility or as described in Section 2.8 any other Abbott facility acceptable to
Scios that is capable of producing Final Product in a manner and quality comparable to the McPherson facility, then Scios may, notwithstanding this Section 2.1.2, arrange for another vendor to provide such services for Scios. 

 
 2.2    Processing Orders.    From time to time as detailed herein,
Scios shall submit to Abbott Processing Orders in substantially the form of Exhibit A for such quantities of Product as Scios requests. 
  
 2.2.1    Scios shall, within [*****] after filing its NDA for the Product, provide Abbott with a written estimate of Scios’ monthly orders for the Product from
Abbott for the first contract year. Abbott acknowledges that such quantities are estimates only. 
  
 2.2.2    Abbott and Scios shall cooperate fully in estimating and scheduling production for the first commercial order to be placed by Scios in anticipation of FDA approval of the Product. 

 
 2.2.3    Scios shall place its first firm Purchase Order approximately
[*****] in advance of the anticipated NDA approval date or desired Product availability date. At the same time, Scios shall provide to Abbott Scios’ estimate of its monthly orders for [*****]. 
  
 2.2.4    Thereafter, Scios shall provide [*****] to Abbott a [*****] forecast of
orders with the [*****] consisting of firm Purchase Orders and the [*****] consisting of Scios’ best estimate forecast of its Product orders. Within [*****], Abbott shall advise Scios of the date Abbott will perform the
Fill and Finish Work specified by such forecast. Each Processing Order submitted by Scios to Abbott shall reference the Fill and Finish date provided by Abbott in 
 
 *****    Confidential portions of this material have been omitted and filed separately with the Securities and Exchange Commission. 

 
 4 

 
 Confidential Treatment Requested 
 
  
 response to the most recent forecast and shall become firm and non-cancelable by Scios if not modified by notice from Scios to Abbott [*****]. 

 
 2.2.5    If, due to significant unforeseen circumstances, Scios requests changes to
firm orders [*****], Abbott shall attempt within reasonable manufacturing capabilities and efficiencies to accommodate the changes. Abbott shall advise Scios of the costs associated with making any such change and Scios shall be deemed to
have accepted the obligation to pay Abbott for such costs if Scios indicates to Abbott that Abbott should proceed to make the change. 
  
 2.2.6    Each Purchase Order or any acknowledgment thereof, whether printed, stamped, typed or, written, shall be governed by the terms of this Agreement and none of the
provisions of such Purchase Order or acknowledgment shall be applicable except those specifying quantity ordered, delivery dates, special shipping instructions and invoice information. 
  
 2.2.7    Not later than [*****], Abbott shall provide to Scios the suggested modifications to Exhibit C necessary to
reflect the size of the batch to be processed and the parties shall then work together to finalize the Exhibit C to be applicable for that Process Order. 
  
 2.2.8    Within [*****], Abbott shall deliver the requested Product to Scios’ Mountain View, California facilities
(or such other destination specified in the Processing Order), F.O.B. McPherson, Kansas. Abbott shall use carriers requested by Scios. Risk of Loss of Product shall be determined in accordance with the provisions of Section 6.2(b) hereof. The
foregoing [*****] is contingent on Scios paying a one-time stocking fee to Abbott for the purchase of [*****]stoppers, vials and seals to be maintained in inventory by Abbott for the purpose of fulfilling Processing Orders hereunder.
Such payment shall not exceed [*****] and shall be made prior to Scios’ delivery of its initial Processing Order. To the extent such stoppers, vials and seals are consumed in the fulfillment of a particular Processing Order, Abbott will
restock them for use in manufacturing Product under this Agreement, or the cost of such materials shall be credited back to Scios. To the extent the terms of any Processing Order are inconsistent with the terms of this Agreement, this Agreement
shall control. 
  
 2.2.9    Each July, Scios and Abbott shall develop a
[*****] forecast and implementation plan containing both an upside and downside forecast of Scios’ anticipated orders and Abbott’s plans for meeting Scios’ anticipated needs. Such long-term forecast shall be non-binding.

  
 2.3    Bulk BNP.    Scios shall supply all Bulk BNP
for the manufacture of the Product, F.O.B. McPherson, Kansas, freight prepaid, with an accompanying certificate of analysis and accompanying identification sample attached, to Abbott’s Product manufacturing plant in McPherson, Kansas, at least
[*****]. Such Bulk BNP shall meet the appropriate Specifications as set forth in Exhibit B. Upon receipt of each quantity of Bulk BNP supplied by Scios, and before all of the Bulk BNP is removed from individual containers, Abbott shall accept
such Bulk BNP, and perform an ID test on samples of the Bulk BNP within a reasonable time (but in no 
 
 *****    Confidential portions of this material
have been omitted and filed separately with the Securities and Exchange Commission. 

 
 5 

 
 Confidential Treatment Requested 
 
  
 event later than [*****]following receipt) in the manner set forth in the Specifications for Bulk BNP in Exhibit B, and shall give Scios prompt written notice of the results of the test. If the
Bulk BNP passes the ID test it shall be accepted by Abbott as meeting such Specifications, and it may be used by Abbott in performing work under this Agreement. Scios shall endeavor to give Abbott at least [*****] notice if Scios anticipates
that it will not be able to use a scheduled production date. If Abbott is unable to complete any Processing Order due to Scios’ failure to supply an adequate quantity of Bulk BNP meeting Specifications, then (A) Abbott shall, if requested by
Scios, perform the run to the extent material is available and deliver the resulting Product to Scios, whereupon Scios shall pay Abbott in accordance with Section 4 or (B) the run shall be postponed until a mutually agreed date and a sufficient
quantity of Bulk BNP becomes available whereupon Abbott shall endeavor to utilize for another client’s or one of Abbott’s own products the facility time allocated to that Processing Order and (i) if Abbott is successful in finding such
replacement work then Scios shall owe Abbott for such inconvenience an amount not to exceed [*****] (ii) if Abbott is unable after reasonable efforts to find such replacement work then Scios shall owe Abbott for such inconvenience an amount
not to exceed [*****]. 
  
 2.4    Raw Materials, Containers and Packaging, Special
Equipment.    Abbott shall manufacture and supply, or purchase from a third party approved by Scios and supply where indicated in Exhibit B, Raw Materials, Containers and Packaging meeting the applicable Specification
necessary to produce Product. Suppliers with whom Abbott contracts are listed in Exhibit B, and after a supplier has been chosen by Abbott and approved by Scios, Abbott shall not change such source of supply without Scios’ prior written
approval. Abbott shall be responsible for performing supplier audits on suppliers providing Raw Materials to Abbott. Scios shall be responsible for performing the FDA-required annual supplier audit on Raw Material suppliers providing material to
Scios which in turn provides said Raw Material to Abbott. When Raw Materials and Containers and Packaging are received by Abbott from the supplier, Abbott shall confirm conformity with the applicable Specification set forth in Exhibit B, and prepare
a release document documenting such conformity and the suitability of each item to be released for use in Manufacture of Product. Scios shall provide the text and format for all necessary labels/labeling for the Containers and Packaging for each
unit of Product, as well as for the shipping container, and unless otherwise agreed, Abbott shall arrange for the printing of such labels/labeling in a timely matter. Scios shall have approved proofs of all such labels/labeling in writing in advance
of printing. Labels/labeling approved by Scios shall be the only labels/labeling used by Abbott for Product, provided, that such labels and package inserts shall be consistent with FDA’s and Abbott’s requirements with regard to physical
dimensions and specifications relating to the methods of handling and affixing on containers. Scios shall provide Abbott with the authorization to purchase printed materials and all other Raw Materials, Containers and Packaging on the Processing
Orders placed by Scios. Scios shall reimburse Abbott for the cost of any inventories of printed materials, Raw Materials and Container Closures ordered by Abbott based on Scios’ authorization that become obsolete due to labeling changes
required by Scios or the FDA and a reasonable charge based on [*****]. Any revision by Scios in the labeling or packaging material will be implemented by Abbott but the cost of preparing die changes shall be paid by Scios. 

 *****    Confidential portions of this material have been omitted and filed separately with the Securities and Exchange Commission. 

 
 6 

 
 Confidential Treatment Requested 
 
  
 In the event that Abbott requires special equipment in order to perform the Fill and Finish Work and such equipment will only be used to produce Product, then Abbott shall
define the cost of the required equipment. Scios must give its prior written approval before the actual purchase of the equipment. The parties shall agree in an addendum to this Agreement to the terms of the purchase and issues relating to ownership
and use. 
  
 2.5    Specification Changes.    All
Product shall be produced in accordance with the procedures set forth in the Batch Record attached as Exhibit C and amended from time to time and all Product shall meet the applicable Specifications set forth solely in Exhibit B as of the date of
manufacturing at Abbott. Abbott shall perform all analytical and in-process testing necessary to show conformity to the Specifications set forth in Exhibit B. If Abbott is unable to perform all such services, the fee payable to Abbott shall be
reduced by [*****]. Abbott shall provide [*****] prior notice of any intended change to equipment that Abbott is aware will be, or was listed in, the NDA filed by Scios for the Product. Abbott shall without additional charge assist
Scios in preparing any submission of information and/or conducting any validation required to obtain FDA approval for such change of equipment. Abbott shall at its cost be responsible for the completion of any validation required in connection with
obtaining FDA approval for the equipment change. No modification in the control documents (as defined in 21 C.F.R. Part 211.186) relating to the manufacturing procedure, quality assurance/control procedures or procedures to assure compliance with
the Specifications shall be made without Scios’ prior written approval. Scios shall have the right to modify the Specifications (Exhibit B) and Batch Record (Exhibit C) from time to time. Any change made shall apply only to production batches
produced after changes are accepted by Abbott. If Scios notifies Abbott of a proposed modification, Abbott shall advise Scios within [*****] whether the modification is feasible and if it is, the estimated changes, if any, in the costs,
delivery time or other terms which would result from such modification. Notwithstanding the foregoing, the modification shall be implemented by Abbott only upon Abbott’s reasonable consent and specific written authorization by Scios after
receipt of such estimate and agreement on appropriate modifications to Exhibit B or Exhibit C. Abbott shall notify Scios of equipment and/or facility changes that might effect any Scios filing with the FDA, providing Abbott is aware of said filing.
Abbott and Scios shall work together to prepare regulatory filings or amendments on said equipment and/or fileable changes. 
  
 2.6    Lot Numbering.    Scios shall designate on each Processing Order the lot number to be used by Abbott in its records concerning Product Manufactured and Tested
according to that Processing Order and to identify such Product. 
  
 2.7    Process
Documentation.    Scios shall be responsible for obtaining all necessary Regulatory Approval for the clinical testing, marketing and sale of Product. Abbott agrees to provide to Scios all information necessary for Scios
to prepare the Chemistry Manufacturing and Controls Section of Scios’ NDA for the Product. Abbott presently has a single Type 1 Drug Master File #2869 on file with the FDA. Abbott shall make available to Scios for inspection and copying (at
reasonable times and upon reasonable notice to Abbott) any of the procedures and methods listed in Exhibit B as the same may be amended from time to time and shall, upon Scios’ written request, send a letter to the FDA authorizing FDA to
reference any appropriate 
 
 *****    Confidential portions of this material have been omitted and filed separately with the Securities and Exchange
Commission. 

 
 7 

 
 Confidential Treatment Requested 
 
  
 Drug Master File on behalf of the Scios application, as might be necessary for Scios’ filings with the FDA or to obtain NDA approval from the FDA based on Abbott’s participation as formulator
and manufacturer of the Product as contemplated by this Agreement. Abbott shall also provide such other assistance (including granting Scios the right to reference any of Abbott’s Drug Master Files if additional filings are made by Abbott) as
Abbott can reasonably provide to support Scios’ efforts to obtain Regulatory Approval for Fill and Finish Work of Product by Abbott. 
  
 2.8    Batch Records.    Abbott shall manufacture all batches in accordance with the procedures set forth in the Specifications (Exhibit B) and Batch Record
(Exhibit C), as modified from time to time, and in compliance with current Good Manufacturing Practices. Abbott will not release any batch except in conformance with FDA regulations. If requested by Scios, Abbott shall make available to Scios for
each Product batch, copies of the Master Production and Control Records and a certificate of analysis, all appropriately signed and dated, as might be necessary to demonstrate compliance with current Good Manufacturing Practices and the procedures
set forth in Exhibit B and Exhibit C. In addition, Abbott shall, if requested by Scios, allow review of its primary laboratory and process documents relating to such Master Production and Control Records and with good cause provide selective copies
if requested by Scios. If Abbott intends to make any material deviations from Exhibit B or Exhibit C for a particular Processing Order, Abbott shall notify Scios and obtain Scios’ prior approval before implementing any such material deviation.
If Abbott becomes aware of any unplanned material deviation from such procedures and controls it shall advise Scios promptly and also specifically describe the unplanned material deviation in such Procedures in the batch records delivered to Scios.
Scios shall have the right to take into account the effect of any unplanned material deviation in determining whether Product meets the warranties set forth in Section 11.1. Abbott shall maintain all Master Production and Control Records for the
time period required by FDA regulations. 
  
 2.9    Inventory, Storage and Shipping
Requirements.    Scios and Abbott will cooperate to maintain adequate inventory at Abbott of Raw Materials and Containers and Packaging so that delivery of all Product to Scios pursuant to an applicable Processing Order
will be made in accordance with Section 2.2. Abbott shall store all supplies related to the Fill and Finish Work in accordance with applicable FDA regulations. Abbott shall also furnish cold storage (2-8°C) for Product, in-process material and
Bulk BNP. Abbott shall store Product free of cost to Scios until completion of quality acceptance by Scios. After quality acceptance, Scios shall pay Abbott at the rate of [*****]. Abbott shall not be obligated to store more than
[*****] at any one time. Abbott shall ship Product to Scios or a location designated by Scios on cold storage (2-8°C) using carriers specified by Scios. 
  
 2.10    Recovery of Bulk BNP; Destruction of Line Rejects.    If requested by Scios, Abbott shall, to the extent
reasonably practicable under the circumstances, recover all Bulk BNP which it is unable to convert into Product and return all such recovered Bulk BNP to Scios. Abbott shall destroy normal line rejects in accordance with the Material Safety Data
Sheet (Exhibit D) and account to Scios for the materials consumed on the batch record. 
 
 *****    Confidential portions of this material have been
omitted and filed separately with the Securities and Exchange Commission. 

 
 8 

 
 Confidential Treatment Requested 
 
  
 2.11    Location.    Except for subcontracts permitted pursuant to Section 2.12 below, all Fill and Finish Work to be
performed by Abbott under this Agreement shall be performed at Abbott’s plant in McPherson, Kansas. 
  
 2.12    Subcontracting.    No Fill and Finish Work under this Agreement shall be subcontracted without Scios’ prior written consent. Abbott shall ensure that all permitted
subcontracts shall include appropriate provisions providing Scios with the same rights as set forth in Section 2.7 and 2.8 in respect of the subcontracted work, including but not limited to, rights to obtain documentation of processing and
validations which can be used in Scios’ own filings for Regulatory Approval of such subcontractor. 
  
 2.13    Delivery and Acceptance.    Unless otherwise directed by Scios, Product shall be shipped to Scios’ facility in Mountain View, California. In the event Scios
directs Abbott to ship Product directly to another recipient, then Scios’ shipping order shall evidence acceptance of the Product. It will be the responsibility of Scios to ensure that any alternate recipient has adequate storage facilities to
receive and store Product under proper storage conditions. Scios shall have the responsibility for acceptance or rejection of Product as meeting the requirements of Section 10.1 which shall occur [*****]. If Scios fails to notify Abbott by
the end of the [*****] period, the lot shall be automatically accepted by Scios as meeting all testing requirements. 
  
 2.14    Validation.    All components, equipment and processes used by Abbott shall be validated consistent with the requirements of all applicable FDA regulations. If
Abbott receives any directive from the FDA concerning validation of Product required at Abbott, Abbott shall inform Scios and the parties shall discuss the alternative means to satisfy the FDA’s directives. Abbott shall be responsible for all
validation activities for components, equipment, and processes that are currently used in Abbott’s manufacturing facility as related to the manufacture of Product. If additional validation is required to be performed for Product, such
additional validation shall be performed by Abbott and at Scios’ cost. Scios will have approval signature for all validation projects initiated upon Scios’ request. Abbott’s estimated validation costs based on Scios’ validation
protocol at the present time are [*****]. Three lots shall be validated by Abbott by obtaining and marking distribution samples from the lyophilization process which will be shipped to Scios for Scios’ testing and approval at Scios’
cost. No validation shall be performed for the secondary packaging, since the final secondary packaging shall be a replica of existing packaging of Product that Abbott is using at its McPherson facility. All costs for validation work under this
Section 2.14 must be agreed to by Scios prior to commencement of any validation work for which Scios is financially responsible. In addition, as detailed in 3.2, Scios has the right to review all protocols, data and summary reports that detail
validation activities related to components, equipment, and processes directly related to the manufacture of Product. 
  
 2.15    Quality Assurance Audits by Scios.    So that Scios may discharge its obligations under FDA regulations, Abbott agrees that Scios may conduct annual quality assurance
inspections and audits of the records and manufacturing and storage facilities of Abbott by up to two representatives of Scios at a time during normal working hours for the purpose of confirming that the Fill and Finish Work is being performed in
compliance with this Agreement 
 
 *****    Confidential portions of this material have been omitted and filed separately with the Securities and
Exchange Commission. 

 
 9 

 
 Confidential Treatment Requested 
 
  
 and applicable regulatory requirements. Scios employees shall follow the safety procedures of the Abbott facility. 
  
 2.16    Facility and Organizational Changes.    Abbott shall inform Scios in advance of any planned facility
and organizational changes that could affect or modify manufacture of Product. Should any proposed modification raise concerns by Scios, the parties shall meet and endeavor to accommodate the reasonable needs of both parties; provided, however, that
Abbott shall have the right to make such change so long as the Product shall continue to be subject and meet the Specifications and the Fill and Finish Work shall continue to be subject to the requirements of this Agreement. 
  
 2.17    Kansas Administrative Requirements.    Abbott agrees to use its reasonable
efforts to maintain all necessary Kansas administrative approvals required to perform the Fill and Finish Work. Abbott shall be responsible for [*****] and Scios shall be responsible for [*****]. 
  
 2.18    Alternative Abbott Facilities.    In the event that Abbott is unable at any
time to Fill and Finish Product in its McPherson, Kansas facility, Abbott will, at Scios’ request, transfer as promptly as is commercially reasonable the manufacture of Product for Scios to another facility of Abbott which has available,
comparable capacity and quality. In such event, Scios shall be responsible for reimbursing Abbott for the reasonable additional costs to Abbott of validating such alternative facilities as agreed by the parties in advance of the transfer.

  
 Section 3.—Fill and Finish Program Management 
  

3.1    Control.    The parties will cooperate in the management of the Fill and Finish Work so as to
assure its completion in the most effective manner. Subject to Section 2.5 hereof, it will be the responsibility of Scios to make all final decisions with regard to the Specifications for the Fill and Finish Work required to be performed by Abbott
hereunder, except any specific directives that Abbott may receive from the FDA, provided that Scios shall first be informed of the directive, and Abbott and Scios shall discuss any alternative means to satisfy the FDA’s requests. Abbott shall
be notified in advance of any specification changes for Fill and Finish work. 
  
 3.2    Access.    Representatives of Scios (including representatives of any BNP licensee of Scios), upon reasonable notice to Abbott, shall have such full and complete
access as is reasonably necessary to observe, monitor and inspect any Fill and Finish Work performed under this Agreement, the manufacture and control of any batch, all equipment and materials employed therein, all Product produced thereby and all
Data as specified in Section 3.3. All representatives of Scios and its licensees shall follow the safety procedures of Abbott. Any representative of Scios or a BNP licensee of Scios shall execute a reasonable confidentiality agreement in favor of
Abbott before being allowed access to Abbott’s facilities. 
  
 3.3    Data
Collection.    Abbott shall maintain good and sufficient records of the results of testing and manufacture of Bulk BNP, Raw Materials, Containers and Packaging and Product in sufficient detail and in accordance with good
manufacturing practices as will properly reflect 
 
 *****    Confidential portions of this material have been omitted and filed separately with the
Securities and Exchange Commission. 

 
 10 

 
 Confidential Treatment Requested 
 
  
 all Fill and Finish Work done and results achieved in the performance of the Fill and Finish Program (including all Data in the form required under any applicable regulations promulgated by the FDA and
including any work done under permitted subcontracts). Copies of any Data produced, generated or procured during the Fill and Finish Program and Master Production and Control Records, including relating to work done under any permitted subcontracts,
shall be delivered to Scios within 7 days of any written request by Scios. In lieu of delivery of any such records to Scios, Abbott agrees to permit a representative of Scios pursuant to Section 3.2 above to examine and review, at reasonable times
upon reasonable notice to Abbott, such records then in Abbott’s possession and to make or have made copies of any such records (at Scios’ expense) as Scios may reasonably request. Abbott shall use such records that are specific and unique
to Scios only as required by Abbott in the fulfillment of its obligations under this Agreement or for the review by management personnel, by regulatory authorities during IND or NDA review or during facility compliance audits by the FDA, State of
Kansas or any other regulatory authority having jurisdiction over Abbott’s Fill and Finish business. 
  
 Section
4.—Price and Payment 
  
 4.1    Scios shall pay Abbott for supplying
Product as requested by Scios on each Processing Order pursuant to Section 2.2 above at the Price per Vial. The Price per Vial includes [*****]. Scios’ payment shall be due [*****]. Abbott shall maintain accurate records and shall
maintain accurate supporting documents to verify each invoice it submits. Such records and documents shall be available for audit by Scios during normal business hours and on reasonable notice but not later than the end of the calendar month after
the calendar month in which the invoice is rendered; provided, that records and documents relating to any charges in dispute shall be retained until the disagreement is resolved. Except as specifically set forth in this Agreement (including, without
limitation, Sections 2.3 and 2.4), Scios shall only be obligated to pay for services related to Product meeting the Specifications. The “Price per Vial” shall mean [*****]. The final vial label and packaging shall be defined by
Scios, and Abbott shall prepare for approval by Scios a revised Price per Vial that also includes [*****]. 
  
 4.2    Abbott shall process [*****] to Scios of Product per batch at no processing charge to Scios. Any additional shipments requested by Scios shall be provided at a processing fee of [*****].
Product shall be shipped F.O.B. Abbott-McPherson. 
  
 Section 5.—Interactions with Governmental Agencies

  
 5.1    Each party agrees to promptly provide the other with copies of any letters,
reports, or the like received by such party from the FDA or other governmental agency including: Form 483s, Form 482s, warning letters, inspection reports, seizure notices, prosecution, injunction, and market withdrawals; provided, such
letter, report, or the like either (1) relates to Product or components thereof or (2) does not relate to Product or components thereof but does relate to other pharmaceutical manufacturing activities or practices affecting Abbott’s processing
of BULK BNP or that may directly relate to the Fill and Finish Work of Product. In particular, if either party is notified that the FDA wishes to inspect its facility in connection with Fill and Finish Work of Product or the records related thereto,
the notified party shall immediately advise 
 
 *****    Confidential portions of this material have been omitted and filed separately with the
Securities and Exchange Commission. 

 
 11 

 
 Confidential Treatment Requested 
 
  
 Scios of such inspection and report to Scios the outcome of such inspection and consult with Scios on any responses that may concern the manufacturing and testing operations directly related to the
Fill and Finish Work of Product. If the inspection is specifically to observe the Fill and Finish Work of Product or is specifically related to the production of Product, Abbott shall permit Scios to observe such inspection if Scios can arrange for
a representative to attend the inspection at the time desired by the FDA. Abbott shall be in charge of any and all regulatory inspections of its facilities, and Scios shall be present as an observer. 
  
 Section 6.—Title and Risk of Loss 
  
 6.1    Title.    Title to all Bulk BNP shall at all times be in Scios and Bulk BNP shall be used by Abbott only for the purposes of and in
accordance with this Agreement. Except for title to Bulk BNP, title to all in-process materials, Raw Materials, Containers, and Product shall be in Abbott until shipped to Scios. 
  
 6.2    Risk of Loss. 
  
 (a)    Transit to Abbott.    Scios shall bear the risk of loss of Bulk BNP, including the risk of spoilage, until delivered to Abbott’s McPherson, Kansas facility.

  
 (b)    At Abbott’s Facility.    Except as otherwise set forth
below concerning the time Abbott is actually conducting Fill and Finish Work, the risk of loss of all Bulk BNP, in-process materials, Raw Materials, Containers and Product shall be in Abbott until shipped as Product or otherwise to Scios. In the
event of such loss, Abbott shall be liable for the cost to replace such materials. The risk of loss of Bulk BNP, in-process materials, Raw Materials, Containers and Product during the time that Abbott is actually conducting Fill and Finish Work
shall be in Scios so long as Abbott conducts all such Fill and Finish Work in adherence with the then current Specifications (Exhibit B) and Batch Record (Exhibit C) but shall be in Abbott when any such materials are consumed or rendered unusable
because Abbott did not adhere to the then current Specifications or Batch Record; provided, however, that Abbott’s maximum obligation to reimburse Scios for the cost of Bulk BNP consumed or rendered unusable due to failure to adhere to such
Specifications or Batch Record by Abbott shall not exceed [*****]. In the event Bulk BNP is consumed or rendered unusable due to such a failure by Abbott to adhere to the Specifications or Batch Record, Scios shall incur no charge from Abbott
with respect to processing such lot. 
  
 (c)    Cost of
Recovery.    In the event the yield of Product from the Bulk BNP supplied by Scios is less than that number of vials that is called for by the Specifications, Abbott shall attempt to recover as much of the Bulk BNP as
feasible, taking into account reasonable line losses. The expense of such recovery and shipping costs shall be borne by Abbott if the failure to produce Product meeting the applicable Specifications was due to Abbott’s failure to adhere to all
of the procedures set forth in Exhibit C, and shall be borne by Scios if the failure was not due to Abbott’s failure to adhere to all of the procedures set forth in Exhibit C. For purposes of this subsection 9(c), “recover” shall mean
physically collect from tailings or vessels, or rework or re-lyophilize
 
 
 *****    Confidential portions of this material have been omitted and filed separately with the
Securities and Exchange Commission. 

 
 12 

 
 Confidential Treatment Requested 
 
 
within the limits of the Fill and Finish Program and within the Regulatory Approval documentation. 
  
 Section 7.—Inventions and Licenses 
  
 7.1    Exchange of Know-How.    Scios and Abbott intend to cooperate and exchange as required Scios Patents, Scios Know-How, Abbott Patents and Abbott Know-How which relate
to or are required for the production of Product, all for the purpose and with the objective of completing the Fill and Finish Work in an expeditious and efficient manner. Such exchange shall include without limitation the disclosure by Abbott of
improvements relating to the manufacture of Product when performing Fill and Finish Work. This exchange is not intended to negate the parties’ obligations under Section 9 nor shall anything in this Section 7.1 be construed to modify the
provisions of Section 10.3 hereof. 
  
 7.2    Ownership of Fill and Finish
Technology.    Abbott shall own the entire right, title and interest in and to improvements (“Improvements”) of the Fill and Finish Work. Abbott agrees that no additional compensation shall be due from Scios to
any Abbott employee assigning rights in such Improvement to Abbott. Abbott shall have the right, but not the obligation, to file and prosecute applications for patents in the United States and all other countries which are directed to Improvements,
and Scios shall render all reasonable assistance in connection therewith at Abbott’s request and expense. Abbott shall advise Scios promptly of the filing of any patent application covering the Improvements and provide in confidence to Scios a
copy thereof. 
  
 7.3    Licenses. 
  
 (a)    License from Scios to Abbott.    For the sole purpose of performing Fill and Finish
Work of Product under this Agreement, Scios hereby grants Abbott, and Abbott hereby accepts from Scios, a nonexclusive, nontransferable, royalty-free, non-sublicensable license to use Scios Patents and Scios Know-How to manufacture Product
exclusively for Scios and to perform its other obligations hereunder. 
  
 (b)    License from
Abbott to Scios Upon Inability to Perform.    In the event Abbott fails for any reason (including without limitation bankruptcy, fire, refusal to supply or insufficient capacity, but excluding a breach of material term of
this Agreement by Scios) to deliver Product pursuant to the terms of this Agreement for [*****], Abbott shall grant, and does hereby grant to Scios, and Scios hereby accepts from Abbott, a nonexclusive, royalty-free, license to use Abbott
Patents, Abbott Know-How and Improvements directly relating to Abbott’s Fill and Finish Work of Product, to manufacture Product solely for the manufacture of Product for Scios. Such license shall include the right of sublicense solely for
purposes of fulfilling Scios’ requirements for Product, shall not extend to a sub-sublicensee, and shall be under obligations of confidentiality no less stringent than those contained in this Agreement. The foregoing license shall not include
any Abbott patents or other technology not used in the production of the Product. 
 
 *****    Confidential portions of this material have been omitted
and filed separately with the Securities and Exchange Commission. 

 
 13 

 
 Confidential Treatment Requested 
 
  
 7.4    Patent Infringement. 
  
 (a)    Abbott.    Abbott shall defend at its own expense any actions brought against itself or Scios, alleging that the manufacture of Product produced by Abbott infringes any
claim of any United States or foreign patent or other proprietary right of a third party and shall pay all damages and costs finally awarded in such action; provided however, that this obligation shall arise only to the extent that such alleged
infringement arises out of Abbott’s use of Abbott Patents, Abbott Know-How or Improvements, and no obligation shall arise to Abbott to the extent the infringement is alleged to be the result of the use of Scios Patents or Scios Know-How.

  
 (b)    Scios.    Scios shall defend at its own expense any actions
brought against itself or Abbott, alleging that the manufacture, use or sale by or for Scios of Product infringes any claim of any United States or foreign patent or other proprietary right of a third party and shall pay all damages and costs
finally awarded in said action; provided however, that this obligation shall arise only to the extent that such alleged infringement arises out of Scios Patents or Scios Know-How, or to the extent that such claim is based solely on the fact that the
subject matter of Abbott’s work is BNP, and no obligation shall arise to the extent the infringement is alleged to be the result of the use of Abbott Patents, Abbott Know-How or Improvements. 
  
 Section 8.—Trademarks and Names on Labels 
  
 Scios shall have the sole authority to select and use trademarks for the Product and shall bear all the costs associated with such selection. Scios shall be responsible for
filing and prosecuting applications for such trademarks, as well as maintaining such trademarks, all in the manner it deems appropriate and shall be the owner of record for all applications and registrations that issue from these applications. Scios
shall bear all costs associated with any of the foregoing. Abbott shall provide such assistance, at Scios’ expense, as Scios reasonably deems necessary in accomplishing any of the foregoing. Scios shall defend, indemnify and hold Abbott
harmless from and against all claims, demands, liabilities, damages, costs and expenses (including attorneys’ fees) in respect to the alleged infringement of trademark, trade name or other similar rights of third parties arising out of the sale
and marketing of the Product by Scios. In no event shall Abbott be responsible for the content of any label or otherwise liable for any failure to supply adequate warnings or to comply with the requirements of 21 C.F.R. Part 201, except as such
failure is due to Abbott’s failure to (i) provide Scios with relevant information regarding Products produced by Abbott, or (ii) affix such labels or package inserts on or in the Product pursuant to the Specifications. Abbott consents to the
appearance of its name on labels to the extent required by FDA regulations or the regulations of any comparable governmental agency outside of the United States subject to Abbott’s reasonable approval of conformity with Abbott’s trademark
protection program. 
  
 Section 9.—Confidentiality 
  

9.1    Nondisclosure.    In connection with its activities relating to this Agreement, either party may
disclose to the other confidential, proprietary information including, but not limited to, 
 
 *****    Confidential portions of this material have been
omitted and filed separately with the Securities and Exchange Commission. 

 
 14 

 
 Confidential Treatment Requested 
 
  
 all business plans, testing methods, and market plans, drawings, specifications, flow sheets, reports, pre-clinical and clinical studies, market studies, software and other technical and marketing
information as well as, proprietary know-how (“Proprietary Information”). Proprietary Information shall also include Scios Patents, Scios Know-How, Abbott Patents, Abbott Know-how, and Improvements. During the term of this Agreement and
for [*****], neither party shall disclose or use Proprietary Information provided to it hereunder by the other party, or allow it to be used, for its own benefit or for the benefit of others, and shall protect Proprietary Information using
the same degree of care used to protect its own information of a similar nature. Proprietary Information shall mean that which is disclosed, directly or indirectly, by either party to the other, in writing, marked “confidential,”
“restricted,” “proprietary” or the like, or, if transmitted orally or by observation of equipment, confirmed in writing within thirty (30) days of its oral or observed disclosure hereunder and marked “confidential,”
“restricted,” “proprietary,” or the like, or with words having the same effect, except any portion thereof which: 
  
 (a)    enters the public domain through no fault of the party to whom the same were disclosed (the “receiving party”); or 
  
 (b)    is in the future legally received by the receiving party from a third party free of any obligation to keep it confidential; or 

 
 (c)    is lawfully in the possession of the receiving party prior to receipt from the disclosing party,
which fact shall be provable by contemporaneous documentary evidence; or 
  
 (d)    is
independently developed by the receiving party without the use of Proprietary Information, as evidenced by its written records; or 
  
 (e)    is required to be disclosed pursuant to a lawful request, order or demand of any governmental agency or judicial authority; provided, however, that protective orders or other reasonable assurances
of confidentiality are received to the extent reasonable available from such agency or authority; and provided, further, that the disclosing party (i) gives the other party notice of the request or order and reasonable time to object, (ii) follows
any proper instructions of the other party regarding such disclosure or objections, and (iii) limits the disclosure to compliance with the lawful request. 
  
 9.2    Duties Upon Termination.    This Section 9 shall inure to the benefit and be enforceable by the parties and their respective
successors. Except to the extent reasonably necessary for exercising its rights which survive termination of this Agreement, upon request by the disclosing party after such termination, the receiving party shall return all Proprietary Information of
the disclosing party in its possession, and in any event shall make no further use of such Proprietary Information, except that one copy of the Proprietary Information be retained in the legal department of the company for purpose of documenting the
Proprietary Information which was received. 
 
 *****    Confidential portions of this material have been omitted and filed separately with the
Securities and Exchange Commission. 

 
 15 

 
 Confidential Treatment Requested 
 
  
 9.3    Publicity Releases.    Except as required by law or provided otherwise by this Agreement, neither party
may disclose the existence or terms of this Agreement without the prior written approval of the other party. Abbott may not use the name or trademarks or tradenames of Scios in any manner, and Scios may not use the name or trademarks or tradenames
of Abbott in any manner, without the prior written approval of the other. Notwithstanding any provision hereof, each party may disclose that which (a) may be required by Regulatory Authorities in order to receive Product approval or (b) is disclosed
pursuant to a written nondisclosure agreement with a third party for the purpose of evaluating a proposed purchase of all or a portion of the business of Scios or Abbott or Scios’ sublicensing of rights to market the Product. Any inquiry Abbott
receives from news media concerning this Agreement will be reviewed with Scios prior to response. 
  
 9.4    Technical Publications.    Except as required by law, (a) no technical paper, abstract, article, publication or announcement relating to the Scios Patents or Scios
Know-How, whether during the period of performance of this Agreement or in the future, shall be made by Abbott without the written consent of Scios and (b) no technical paper, abstract, article, publication or announcement relating to Abbott
Patents, Abbott Know-How or Improvements, whether during the period of performance of this Agreement or in the future, shall be made by Scios without the written consent of Abbott. 
  
 Section 10.—Warranties 
  
 10.1    By Abbott. 
  
 (a)    Product.    Abbott warrants that all Product delivered to Scios by Abbott hereunder shall conform to the Specifications as modified from time to time. Abbott further warrants that
(i) Product shall be manufactured in accordance with applicable FDA regulations, shall be free from defects in manufacturing workmanship, shall not be adulterated or misbranded, as defined under Section 501 of the Food, Drug & Cosmetic Act (21
U.S.C. Section 501) (the “Act”); (ii) the water for injection used as a Raw Material shall meet U.S.P. specifications; (iii) the Raw Materials acquired or manufactured by Abbott shall meet the Specifications as modified from time to time;
(iv) materials supplied but not manufactured by Abbott (including bottles, stoppers, packaging and any administration device) shall be tested according to Abbott’s quality assurance procedures and meet the Specifications when so tested; and (v)
Abbott shall at all times when manufacturing, processing or controlling the Product be, to the extent necessary, properly licensed and registered with all applicable governmental agencies. These warranties shall not apply to any Product (1) to the
extent the nonconformity or adulteration results from the Bulk BNP provided by Scios, provided such Bulk BNP met the Specifications as evidenced by the certificate of analysis sent from Scios to Abbott with each shipment of Bulk BNP, and as
determined by the ID test procedures performed by Abbott on Bulk BNP under Exhibit B to the extent determinable by such ID test and conformed to the Certificate of Analysis for such Lot; or (2) which, after risk of loss thereto has transferred to
Scios, (A) has been tampered with or otherwise altered; (B) has been subjected to misuse, negligence or accident other than by Abbott; (C) has been stored, handled or used by others in a manner contrary to current Good Manufacturing Practices, used
in a manner other than for what was approved by the FDA or any foreign government, or similar requirements; or (D) has expired its stated shelf life. 
 
 *****    Confidential portions of this material have been omitted and filed separately with the Securities and Exchange Commission. 

 
 16 

 
 Confidential Treatment Requested 
 
  
 (b)    Remedy.    Should Scios reject any shipment as nonconforming or should any failure to conform with the foregoing
warranty appear, Scios shall give prompt written notice to Abbott of the basis for rejection or nonconformity. The parties shall then promptly confer to discuss the rejection or nonconformity and attempt to determine what action to take. If after
such discussion Abbott believes that the Product is conforming and Scios continues to believe that it is nonconforming and the basis for rejection is the failure to conform to the Specifications, then the parties shall retain a mutually agreed
independent testing firm capable of performing the tests and assays specified in Exhibit B (the “Testing Firm”) to determine conformity or nonconformity with the Specifications and foregoing warranty. The decision of Testing Firm shall be
binding on both parties in the determination of whether Scios is obligated to pay for Abbott’s services in connection with that delivery. The costs of employing Testing Firm shall be paid by Abbott if Testing Firm finds that the Product is
nonconforming and by Scios if the Product is found to be conforming. At Scios’ option and as Scios’ sole and exclusive remedy hereunder, Abbott promptly shall, at Abbott’s own cost, either (1) replace all nonconforming Product with
reworked conforming Product provided that the rework procedure has been previously submitted to the regulatory authorities, (2) conduct rework according to a plan submitted to and accepted by the FDA, or (3) refund any payments by Scios to Abbott
for such nonconforming Product and, in any event, (x) reimburse Scios for Scios’ cost of any Bulk BNP contained therein that has not been converted to Final Product up to the limit of Abbott’s liability under Section 7.2(b). If Scios
selects option (1) or (2) above, then upon delivery of Product meeting the Specifications it shall pay Abbott for performing the Fill and Finish of such Lot. 
  
 10.2    By Scios. 
  
 (a)    Bulk BNP.    Scios warrants that the Bulk BNP, at the time supplied by Scios to Abbott, shall conform to the Specifications, shall be manufactured in accordance with applicable
FDA regulations, shall be free from defects in manufacturing workmanship, conform to the certificate of analysis related to that batch of Bulk BNP, and that the Bulk BNP shall not be adulterated, as defined under Section 501 of the Act. This
warranty shall not apply to any Bulk BNP after risk of loss thereto has transferred to Abbott that (i) has been tampered with or otherwise altered after shipment from Scios; (ii) has been subjected to misuse, negligence or accident other than by
Scios; (iii) has been stored, handled or used by others in a manner contrary to FDA or similar requirements or Scios’ written instructions; (iv) has expired its stated shelf life which shall be predetermined and defined by Scios to Abbott,
including methods for retain and release if Bulk BNP should expire while in possession of Abbott; (v) has failed to meet the Specifications as determined by the test procedures pursuant to Section 2.3, or (vi) where the nonconformity would have been
discovered if tested in the manner set forth in Section 2.3. 
  
 (b)    Remedy.    Should any failure to conform with the foregoing warranty appear prior to payment for Product Scios shall correct such nonconformity by replacement of the nonconforming
Bulk BNP and by Scios’ reimbursement of Abbott for all reasonable costs incurred by Abbott in connection with such nonconforming material, such costs not to exceed the amounts payable to Abbott for the Fill and Finish Work for such Products or
any rework performed by Abbott in an effort to minimize product loss. 
 
 *****    Confidential portions of this material have been omitted and filed
separately with the Securities and Exchange Commission. 

 
 17 

 
 Confidential Treatment Requested 
 
  
 10.3    Title.    Abbott and Scios warrant that, except as otherwise provided in this Agreement, each has good
and sufficient title, or the right to transfer as provided for herein, to all materials, supplies, processes, patents, know-how and technology furnished to the other or used in the performance of this Agreement. 
  
 10.4    Product Recall.    Except to the extent attributable to a
nonconformity with Abbott’s warranties under Section 10.1 or a subject of indemnification under Section 11.2, Scios shall reimburse Abbott and indemnify it from all reasonable costs and expenses in respect of activities arising out of any
necessary recall of Product authorized by Scios or directed to Abbott by the FDA or in respect of activities arising out of and necessarily required by any recall of Product made pursuant to a final judicial order, including, but not limited to,
reshipment, storage and disposal of recalled Product, preparing and maintaining reports and records, and reasonable internal costs. To the extent attributable to a nonconformity with Abbott’s warranties under Section 10.1 or a subject of
indemnification under Section 11.2, Abbott shall reimburse Scios and indemnify it from all reasonable costs and expenses in respect of activities arising out of any necessary recall of Product authorized by Scios or in respect of activities arising
out of and necessarily required by any recall of Product made pursuant to a directive from a Regulatory Authority, including, but not limited to, reshipment, storage and disposal of recalled Product, preparing and maintaining reports and record,
notifications to any user, and reasonable internal costs, up to [*****]. Abbott shall provide all reasonable assistance to Scios in carrying out any necessary recall. 
  
 10.5    Exclusive Warranties.    Except as expressly provided for in Section 10, Abbott and Scios make no
additional representation or warranties of any nature whatsoever to each other with respect to the Product, Bulk BNP, Raw Materials, Containers and Packaging or other materials supplied hereunder, by either of them to the other, and ALL OTHER
WARRANTIES, EXPRESS OR IMPLIED, INCLUDING IMPLIED WARRANTIES OF MERCHANTABILITY AND OF FITNESS FOR A PARTICULAR PURPOSE ARE HEREBY DISCLAIMED BY ABBOTT, SCIOS, THEIR AFFILIATES AND THEIR SUBCONTRACTORS. 
  
 Section 11.—Indemnification 
  
 11.1    By Scios.    Scios shall be solely responsible for and shall defend, indemnify and hold Abbott harmless from and against all claims,
causes of action, settlement costs, including reasonable legal expenses, losses or liabilities of any kind asserted by third persons which arise out of or are attributable to personal injury suffered or incurred by anyone (including any of
Abbott’s employees) and property damages of any third party to the extent caused by: (i) design or composition defects in the Product, exclusive of components thereof manufactured or purchased by Abbott to the extent that the design or
composition of such components was not specified by Scios; (ii) failure by Scios to comply with the Act and the regulations thereunder; (iii) failure to provide warnings as
 
 
 *****    Confidential portions of this material have been omitted and filed separately with the
Securities and Exchange Commission. 

 
 18 

 
 Confidential Treatment Requested 
 
 
required by law; (iv) the handling, transfusion, perfusion, injection or other use of or exposure to the Bulk BNP or the Product; (v) the Bulk BNP or other materials supplied by Scios; (vi) any
willful act or omission or negligence of Scios or its employees, agents or other contractors in work performed in the production of the Product; (vii) a nonconformity with the warranty under Section 10.2; and (viii) the use of Product as a
pharmaceutical product or the safety or efficacy of Product, except in each of the foregoing to the extent specifically assumed by Abbott under this Agreement or arising out of Abbott’s failure to perform its contractual obligations hereunder.

  
 11.2    By Abbott.    Abbott shall be solely
responsible for and shall defend, indemnify and hold Scios and its third party designees and their distributors harmless from and against all damages attributable to all claims, cause of action, settlement costs, including reasonable legal expenses,
losses or liabilities of any kind asserted by third persons which arise out of or are attributable to any negligent act or omission or willful misconduct on the part of Abbott’s employees, agents and representatives. 
  
 11.3    Employees.    Except as provided above in this Section 11, each party
shall indemnify and hold the other party harmless, and hereby forever releases and discharges the other party, from and against all claims, demands, liabilities, damages and expenses (including attorney’s fees) arising out of personal injury
(including death) or property damage incurred or suffered by the indemnifying party, its contractors or its employees (regular or contract) arising out of or in connection with the work performed hereunder, except to the extent caused by the sole
negligence of such other party, its employees or agents. 
  
 11.4    Notice and
Assistance.    No indemnity under this Section 11 shall be applicable unless the indemnified party gives the indemnifying party prompt notice of any claim, suit, or action brought against the indemnified party and allows
the indemnifying party to defend, manage the defense of, and/or settle the same and renders the indemnifying party all assistance reasonably necessary in defending against such claim, suit, or action. Unless specifically agreed to in writing and in
advance, the indemnified party shall not be liable to participate in paying or reimbursing the costs of any settlement, litigation costs or expenses in and by the indemnifying party. 
  
 11.5    Unenforceability.    The foregoing indemnity obligations of this Section 12 shall not be deemed to
extend to any type of claim, act or omission by Abbott or Scios for which the indemnity obligation would be void, unenforceable or otherwise not permitted by applicable law, and if any are deemed to so extend, it shall be interpreted and restricted
to the extent to which it is permitted by applicable law. 
  
 Section 12.—Termination 

 
 12.1    Term of Agreement.    Unless terminated earlier as
provided in Sections 12.2 or 12.3 below, this Agreement shall continue in full force and effect for 7 years from the Effective Date. This Agreement shall be automatically extended for each successive calendar year unless written notice is given by
one party to the other at least six months prior to the end of the then
 
 
 *****    Confidential portions of this material have been omitted and filed separately with the
Securities and Exchange Commission. 

 
 19 

 
 Confidential Treatment Requested 
 
 
current term (initial or extended) that the party does not wish to continue the Agreement beyond such term. If such notice is given, then this Agreement shall terminate at the end of the then
current term (initial or extended). 
  
 12.2    Termination for
Cause.    Without prejudice to any other rights it may have hereunder or at law or in equity, either party may terminate this Agreement immediately by written notice to the other party upon the occurrence of any of the
following: 
  
 (a)    the other party becomes insolvent, an order for relief is
entered against the other party under any bankruptcy or insolvency laws or laws of similar import, or fails generally to pay its debts as they become due; 
  
 (b)    the other party makes an assignment for the benefit of its creditors or a receiver or custodian is appointed for it, or its
business is placed under attachment, garnishment or other process involving a significant portion of its business; 
  
 (c)    the other party fails to maintain operations as a going business for more than twenty days; 
  
 (d)    after sixty days’ written notice from the terminating party, the other party fails to remedy any material breach of this Agreement. 
  
 12.3    Rights and Duties Upon Termination.    Termination of this Agreement,
for whatever reason, shall not affect any rights or obligations accrued by either party prior to the effective date of termination, including completion of a Processing Order for Product delivered by Scios prior to the effective date of termination.
Without limiting the generality of the foregoing, upon termination of this Agreement after commencement of any Fill and Finish Work: 
  
 (a)    provided that Scios provides adequate assurances for payment, Abbott shall sell to Scios Abbott’s inventory of Product and/or to return to Scios its inventory of Bulk
BNP, in whole or in part, within thirty (30) days following termination. 
  
 (b)    upon any termination, Abbott shall continue to cooperate with Scios pursuant to Section 2.7 and Section 5 in respect of all requirements of the FDA and this Agreement regarding previously produced Product.

  
 (c)    upon any termination, both parties shall immediately cease using the
other party’s Proprietary Information except as permitted by Sections 9.1 and 12.3; 
  
 (d)    subject to any limitation, restriction, prohibition or other regulation of a bankruptcy court of trustee, upon any termination by Scios pursuant to Section 12.2, Abbott shall be deemed to have granted to
Scios the license specified in Section 7.3(b). 
 
 *****    Confidential portions of this material have been omitted and filed separately with the
Securities and Exchange Commission. 

 
 20 

 
 Confidential Treatment Requested 
 
  
 Sections 10, 11, 12, 15, 16 and 17 shall survive any termination of the Agreement, and Section 9 shall survive any termination of the Agreement for the period specified in Section 9.1. 

 
 Section 13.—Insurance. 
  
 Scios shall obtain and maintain, at its own cost and expense, and keep in place general liability insurance, with bodily injury and property limits of two million dollars ($2,000,000) covering product
liability and contractual liability for the indemnity and hold harmless provisions contained in Section 11. 
  
 Section
14.—Compliance With Law 
  
 14.1    Scope.    In the performance of its work under this Agreement, Abbott and Scios shall comply with all applicable federal, state and local laws, regulations and
executive orders, including, but not limited to, current Good Manufacturing Practices in accordance with 21 C.F.R. Parts 210, 211 and 600, any applicable state or Federal law or regulation insofar as applicable to the performance of their respective
obligations hereunder. 
  
 14.2    Assistance by
Scios.    Scios shall furnish reasonable assistance for compliance with Section 14.1 above to the extent such compliance involves the composition, toxicity, safety and other chemical or physical characteristics of Bulk
BNP, including, but not limited to, furnishing the technical data required by all OSHA, EPA, health, safety and fire laws. 
  
 Section 15.—Dispute Resolution 
  
 15.1    Mediation.    If a dispute arises under this Agreement which cannot be resolved by the personnel directly involved, either party may give written notice to the
other party, designating an executive officer with appropriate authority to be its representative in negotiations relating to the dispute. Upon receipt of such notice, the other party shall, within five (5) business days, designate an executive
officer with similar authority to be its representative. The designated executive officers shall, following whatever investigation each reasonably deems appropriate, promptly enter into discussions concerning the dispute and if the dispute is not
resolved within sixty (60) days as a result of such discussion, either party may elect to initiate such other action as it is reasonably entitled under the governing law. 
  
 Section 16.—Limitation of Liability 
  
 IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE, including, but not limited to, loss of
profits or revenue, loss of use of any equipment, cost of capital, down time costs, delays, or claims of customers of any of them or other third parties for such or other damages, except to the extent such damages are allocated under Section 7 or
Section 11. 
 
 *****    Confidential portions of this material have been omitted and filed separately with the Securities and Exchange Commission.

 
 21 

 
 Confidential Treatment Requested 
 
  
 Section 17.—Miscellaneous 
  
 17.1    Choice of Law.    This Agreement shall be governed and interpreted, and all rights and obligations of the parties shall be determined, in accordance with the laws
of the State of Delaware. 
  
 17.2    Force
Majeure.    Abbott and Scios shall not be deemed to be in default nor be liable for any delay in performance, when and to the extent due to causes beyond its reasonable control or from fire, war, acts of God, strike,
labor difficulties, act or omission of any governmental authority, compliance with governmental regulations, insurrection or riot, embargo, delays or shortages in transportation or inability to obtain necessary labor, materials, or laboratory or
manufacturing facilities from usual sources or from defects or delays in the performance of its suppliers or permitted subcontractors due to any of the foregoing enumerated causes. 
  
 17.3    Notices.    All notices, requests, demands, waivers, consents, approval or other communications to any
party hereunder shall be in writing and shall be deemed to have been duly given if delivered personally to such party or sent to such party by telegram or confirmed telefax or by registered or certified mail, postage prepaid, to its address as shown
below: 
  

	          Scios, Inc.: 
 	  2450 Bayshore Parkway 
 

	 	Mountain View, CA 94043 
 

	 	Attention: Vice President of Development 
 

	 	Telefax: (415) 968-2438 
 

 

	          with a copy to: 
 	  2450 Bayshore Parkway 
 

	 	Mountain View, CA 94043 
 

	 	Attention: General Counsel 
 

	 	Telefax: (415) 962-5816 
 

 

	          Abbott Laboratories: 
 	  P. O. Box 1247 
 

	 	1776 N. Centennial Drive 
 

	 	McPherson, KS 67460 
 

	 	Attention: Plant Manager 
 

	 	Telefax: (316) 241-5350 
 

 

	          with copies to: 
 	  Hospital Products Division 
 

	 	200 Abbott Park Road 
 

	 	Abbott Park, IL 60064-3500 
 

	 	Attention: President, Hospital Products Division 
 

	 	Telefax: (847) 937-0805 
 

 

	          and 
 	  100 Abbott Park Road 
 

	 	Abbott Park, IL 60064-3500 
 

	 	Attention: Associate General Counsel, D322, AP6D 
 

	 	Telefax: (847) 938-1206 
 

 *****    Confidential portions of this material have been omitted and filed separately with the Securities and Exchange Commission. 

 
 22 

 
 Confidential Treatment Requested 
 
  
 or to such other address as the addressee may have specified in a notice duly given to the sender as provided herein. Such notice, request, demand, waiver, consent, approval or other communications
will be deemed to have been given as of the date so delivered, telegraphed, telexed, or five days after so mailed. 
  
 17.4    Partial Invalidity.    If, for any reason, any provision of this Agreement shall be deemed by a court of competent jurisdiction to be illegal, invalid or
unenforceable, the validity, legality or enforceability of the remaining provisions of this Agreement shall not in any way be affected or impaired, and such provision consistent with applicable law, and in its modified form, such provision shall be
enforceable and enforced. 
  
 17.5    Entire
Agreement.    This instrument states the entire agreement reached between the parties hereto with respect to the transactions contemplated hereby (Abbott’s Fill and Finish Work) and may not be amended or modified
except by written instrument duly executed by the parties hereto. Any and all previous agreements and understandings between the parties regarding Production of Product after the date of this Agreement, whether written or oral, are superseded by
this Agreement. To the extent the terms of any purchase order or Processing Orders are inconsistent with the terms of this Agreement, this Agreement shall control. The failure of either party hereto to enforce at any time, or for any period of time,
any provision of this Agreement shall not be construed as a waiver of such provision or of the right of such party thereafter to enforce each and every provision. The parties agree that all references to Sanofi Winthrop in the attached exhibits are
references to Abbott Laboratories which has acquired the McPherson facility from Sanofi Winthrop subsequent to the creation of the exhibit. 
  
 17.6    Assignment, Binding Effect.    Neither party shall assign this Agreement, by operation of law or otherwise, without the prior written
consent of the other party, such consent not to be withheld unreasonably and any such attempted assignment without such consent shall be void, except that, subject to Section 13.2 hereof, either party may assign this Agreement to an Affiliate. No
assignment shall be effective until the assignee shall have unconditionally assumed in writing all of the assignor’s obligations hereunder and a written notice of such assignment is given to all the other parties. When duly assigned in
accordance with the foregoing, this Agreement shall be binding upon and inure to the benefit of the assignee. 
  
 17.7    Independent Contractor.    Each party shall be and shall endeavor to act as the independent contractor of the other party. Neither party shall be the legal agent of
the other for any purpose whatsoever and therefore has no right or authority to make or underwrite any promise, warranty or representation, to execute any contract or otherwise to assume any obligation or responsibility in the name of or in behalf
of the other party, except to the extent specifically authorized in writing by the other party. Neither of the parties hereto shall be bound by or liable to any third persons for any act or for any obligation or debt incurred by the other toward
such third party, except to the extent specifically agreed to in writing by the party so to be bound. 
 
 *****    Confidential portions of this
material have been omitted and filed separately with the Securities and Exchange Commission. 

 
 23 

 
 Confidential Treatment Requested 
 
  
 17.8    Headings.    All section headings contained in this Agreement are for convenience of reference only, do
not form a part of this Agreement and shall not affect in any way the meaning or interpretation of this Agreement. 
  
 17.9    Debarment Warrant.    Abbott and Scios represent and warrant that neither party does now or in the future use in any capacity the service of any person debarred
under subsection (a) or (b) of 21 U.S.C. §335a. 
 
 *****    Confidential portions of this material have been omitted and filed separately with the
Securities and Exchange Commission. 

 
 24 

 
 Confidential Treatment Requested 
 
  
 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date and year above written. 
  
 
	 SCIOS INC.
 	 	  	 	 ABBOTT LABORATORIES
 
	 
	 By:
 	 	 /s/    JOHN H. NEWMAN
 
	 	  	 	 By:
 	 	 /s/    JOHN G. KRINGEL
 

	  	 	  	 	  	 	  	 	  
	 
	 Name:
 	 	 John H. Newman
 
	 	  	 	 Name:
 	 	 John G. Kringel
 

	  	 	  	 	  	 	  	 	  
	 
	 Title:
 	 	 Vice President and Secretary
 
	 	  	 	 Title:
 	 	 President Hospital Products Division
 

	  	 	  	 	  	 	  	 	  

 
 
 *****    Confidential portions of this material have been omitted and filed separately with the
Securities and Exchange Commission. 

 
 25 

 
 Confidential Treatment Requested 
 
  
 Exhibits: 
  
 A—Form of Processing Order 
 B—Specifications 
 C—Batch Record 
 D—Material Safety Data Sheet 
  
 See Section 17.5 regarding references to Sanofi Winthrop in the Exhibits 

 *****    Confidential portions of this material have been omitted and filed separately with the Securities and Exchange Commission. 

 
 26 

 
 Confidential Treatment Requested 
 
  
 EXHIBIT A 
  
 PROCESSING ORDER 
  
 
	 Order Number:                                  
                                        
                      
  
 Date:                                    
                                        
                                      
 
 

 
  

	To:
	 
	Abbott Laboratories 
 

	     
	 
	P.O. Box 1247 
 

	     
	 
	1776 N. Centennial Drive 
 

	     
	 
	McPherson, KS 67460 
 

  
 Scios hereby places the following order under the Processing and Supply Agreement between us concerning Abbott’s Manufacturing and Testing of Natrecor® BNP for Scios: 
  
 Quantity

  
 Placebo: ________ vials 
  
 Final Product: ________ vials 
  
 
	 Lot Number to be used for this Product:                         
                     
 	 	  	 	 Product Code #                                 
                                        
                    
 

 
  
 Delivery Dates: 
  
 Bulk BNP to be delivered by Scios to Abbott: not later than ________, 199__, (which date shall not be [*****]. 
  
 Product to be delivered by Abbott to Scios: not later than ________, 199__, (which date shall not be [*****]. 
  
 This Processing Order authorizes Abbott to use the following printed Material, Raw Materials, Containers and Packaging. 
  
 Special instructions (if any): 
 
 *****    Confidential portions of this material have been omitted and filed separately with the
Securities and Exchange Commission. 

 
 27 

 
 Confidential Treatment Requested 
 
  
 EXHIBIT B 
  
 SPECIFICATIONS 
  
 The following documents contain the specifications for Product, Placebo and Raw Materials used to produce Product. Copies of the current
version of the specifications are attached. 
  
 
	 Exhibit
 
	    	 Document Type
 
	  	 Issued by Sanofi
 
	  	 Raw Material
 
	  	 Vendor
 

	 [*****]
 	    	  	  	  	  	  	  	  

 
 
 *****    Confidential portions of this material have been omitted and filed separately with the
Securities and Exchange Commission. 

 
 28 

 
 Confidential Treatment Requested 
 
  
 EXHIBIT C 
  
 BATCH RECORD 
  
 (PROCEDURES AND CONTROLS) 
  
 [*****] 
  
 
 *****    Confidential portions of this material have been omitted and filed
separately with the Securities and Exchange Commission. 

 
 29 

 
 Confidential Treatment Requested 
 
  
 EXHIBIT D 
  
 MATERIAL SAFETY DATA SHEET 

 
 [*****] 
 
 *****    Confidential portions of this
material have been omitted and filed separately with the Securities and Exchange Commission. 

 
 30Cross-License Agreement

 
 Confidential Treatment Requested 
 
  
 Exhibit 10.58 
  
 CROSS-LICENSE AGREEMENT 

 
 This Agreement (“Agreement”) made and entered into as of May 13, 1998 (“Effective Date”), by and between
SHIONOGI & CO., LTD., a Japanese corporation having a principal place of business at 1-8, Doshomachi 3-chome, Chuo-Ku, Osaka 541-0045, Japan (“Shionogi”), and SCIOS INC., a Delaware corporation with a principal place of business at 820
West Maude Avenue, Sunnyvale, CA 94085, U.S.A. (“Scios”), 
  
 WITNESSETH: 
  
 WHEREAS, Scios owns or controls the patent rights listed on Appendix A (the “Scios Patents Rights”) related to the human protein
known as B-type natriuretic peptide (“BNP”); 
  
 WHEREAS, Shionogi owns or controls the patent rights
listed on Appendix B (the “Shionogi Patent Rights”) related to BNP; 
  
 WHEREAS, as a means to avoid a
protracted period of uncertainty due to the opposition of each other’s patent applications and patents around the world, Shionogi and Scios entered into a brief Patent Agreement dated April 28, 1998 (the “April Agreement”) setting
forth the terms of an exchange of patent rights between Shionogi and Scios related to BNP. The April Agreement stipulates, among other things, that further agreements may be prepared by the parties to more fully set forth the understanding contained
in the Patent Agreement; and 
  
 WHEREAS, the parties, through good faith negotiations, have now reached agreement on
the definitive terms to implement the April Agreement. 
  
 NOW, THEREFORE, in consideration of the premises and the
material promises and covenants contained herein, Shionogi and Scios agree as follows: 
  
 ARTICLE I. 

DEFINITIONS 
  
 As used in this
Agreement, the following terms (the singular may include the plural and vice versa) shall have the following meanings: 
  
 1.1    “Affiliate” means, as to a party to this Agreement, any corporation, company, partnership, joint venture or other entity which controls, is controlled by, or is under common control with,
such party. For purposes of this Article 1.1, control shall mean, without limitation: (a) in the case of corporate entities, the direct or indirect ownership of at least fifty percent (50%) of the stock or participating shares entitled to vote for
the election of directors; and (b) in the case of a partnership, the power customarily held by a general partner to direct the management and policies of such partnership; provided, however, in the circumstance where the country of incorporation of
such owned or controlled corporation requires that maximum foreign ownership be less than 50%, the maximum permitted percentage of foreign ownership shall be substituted in this paragraph for 50%. 
 
 *****    Confidential portions of this material have been omitted and filed separately with the Securities and Exchange Commission. 

 
 1 

 
 Confidential Treatment Requested 
 
  
 1.2    “Diagnostic Product” means any in vitro diagnostic test, reagent(s), kit or component thereof specifically used to
measure levels of BNP in biological fluids. 
  
 1.3    “Therapeutic Product”
means any pharmaceutical therapeutic product intended to treat a disease or condition in humans that contains any form of BNP as an active ingredient. 
  
 1.4    “Licensee” means the party to whom Patent Rights have been licensed under this Agreement by the Patent Owner (as hereinafter defined). 

 
 1.5    “Net Sales” means the gross receipts of Scios, its Affiliates and any Sublicensee
(as hereinafter defined) of Scios, from sales of Therapeutic Product in countries in Territory B (as hereinafter defined) within the applicable period, less the sum of the following deductions to the extent actually allowed or borne by Scios, its
Affiliates or any Sublicensee of Scios: (a) transportation charges, and other charges, such as insurance, relating thereto, (b) sales and excise taxes or customs duties paid by Scios or its Affiliates and its Sublicensee(s) and any other
governmental charges imposed upon the sale of the Therapeutic Product, (c) rebates or allowances actually granted or allowed, including government and managed care rebates (d) quantity discounts, cash discounts or chargebacks actually granted,
allowed or incurred in the ordinary course of business in connection with the sale of the Therapeutic Product, and (e) allowances or credits to customers, not in excess of the selling price of the Therapeutic Product, on account of governmental
requirements, rejection, outdating recalls or return of the Therapeutic Product. 
  
 1.6    “Patent Owner” means Scios in the case of the Patent Rights listed on Appendix A and Shionogi in the case of Patent Rights listed on Appendix B. 
  
 1.7    “RIA Product” means an in vitro radioirnmunoassay test, reagent(s), kit or component
thereof used to measure levels of BNP in biological fluids in a test format that employs antibodies to BNP bound to a solid support in bead form. Specifically excluded from the definition of RIA Product is any assay which is capable of being used to
measure BNP levels in a format that is compatible with automated instrument analyzer systems. 
  
 1.8    “Scios Patent Rights” means those existing patents and patent applications listed in Appendix A attached hereto and any substitutions, extensions, reissues, renewals, divisions,
continuations, continuations-in-part, supplementary protection certificates, term restorations, inventor’s certificates and applications or patents claiming common filing priorities therewith, and all foreign counterparts of the foregoing.

  
 1.9    “Shionogi Patents Rights” means those existing patents and patent
applications listed in Appendix B attached hereto and any substitutions, extensions, reissues, renewals, divisions, continuations, continuations-in-part, supplementary protection certificates, term restorations, inventor’s certificates and
applications or patents claiming common filing priorities therewith, and all foreign counterparts of the foregoing. 
  
 1.10    “Sublicensee” shall mean any other party to which Scios or Shionogi grant a sublicense in accordance with Article 3 or Article 4 hereof. 
 
 *****    Confidential portions of this material have been omitted and filed separately with the Securities and Exchange Commission. 

 
 2 

 
 Confidential Treatment Requested 
 
  
 1.11    “Territory A” means all countries of the world except Japan. 
  
 1.12    “Territory B” means all countries of the world. 
  
 1.13    “Territory C” means all countries of the world except Japan and the United States of America. 
  
 1.14    “Third Party” means a party other than (a) Shionogi, and its Affiliates and Sublicensees and
(b) Scios, and its Affiliates and Sublicensees. 
  
 1.15 “Valid Claim” means a claim of an issued
and unexpired patent included in either the Shionogi Patent Rights or in the Scios Patent Rights, which claim has not been held invalid or unenforceable by the final decision, unappealed or unappealable, of a court or agency of competent
jurisdiction, or which has not been admitted by the patentee to be invalid. 
  
 ARTICLE II. 
 TERMINATION OF EARLIER AGREEMENTS 
  
 2.1    Scios and Shionogi intend that this Agreement set forth the entire understanding between them with respect to the exchange of rights and licenses between Scios and Shionogi concerning their respective
patent rights related to BNP. In particular, the parties specifically agree that, as of the Effective Date, this Agreement supersedes and replaces the following agreements previously entered into by them: 
  
 A.    License Agreement (for Japan) dated June 9, 1992. 
  
 B.    Patent License Agreement (for RIA products) dated August 6, 1997. 
  
 C.    The April Agreement. 
  
 The agreements listed in A, B and C above are collectively referred to as the “Terminated Agreements.” Each party agrees that the other party has fully performed
its obligations under the Terminated Agreements and that it has no claim against the other party arising under any of the Terminated Agreements. Shionogi acknowledges [*****]. 
  
 ARTICLE III. 
 RIGHTS GRANTED BY SCIOS 
  
 3.1    Grant for Diagnostic Products in Japan.    Scios hereby grants to Shionogi, subject
to the terms and conditions set forth herein, the exclusive right and license under the Scios Patent Rights to make, have made, use, have used, import, have imported, export, have exported, offer for sale, sell and have sold any Diagnostic Product
in Japan. Shionogi may grant any sublicense in Japan under the rights granted in this Section 3.1 without the prior consent of Scios. 
  
 3.2    Grant for Diagnostic Products in Territory A.    Scios hereby grants to Shionogi, subject to the terms and conditions set forth herein, the semi-exclusive right and
license under the Scios Patent Rights to make, have made, use, have used, import, have imported, export, have exported, offer for sale, sell and have sold any Diagnostic Product in Territory A. Scios reserves
 
 
 *****    Confidential portions of this material have been omitted and filed separately with the
Securities and Exchange Commission. 

 
 3 

 
 Confidential Treatment Requested 
 
 
the right to grant in Territory A, additional licenses under the Scios Patent Rights; provided, however, that Scios agrees that [*****] shall be authorized under licenses granted by Scios under
the Scios Patent Rights within Territory A to make, have made, use, have used, import, have imported, export, have exported, offer for sale, sell, and have sold Diagnostic Products in any country of Territory A. In any country within Territory A,
Shionogi may grant only one (1) sublicense or distributorship under the rights granted in this Section 3.2; provided that (a) such sublicense or distributorship and any further sublicense or distributorship granted thereunder allow only a single
entity to market or sell Diagnostic Products in such a country and (b) Shionogi itself does not also simultaneously market or sell a Diagnostic Product in that country. 
  
 3.3    Grant for RIA Products in Territory.    Scios hereby grants to Shionogi, subject to the terms and conditions set forth
herein, the non-exclusive right and license under the Scios Patent Rights to make, have made, use, have used, import, have imported, export, have exported, offer for sale, sell and have sold any RIA Product in Territory C. Specifically excluded from
the license granted herein are (a) any product containing BNP which is used or intended for use or administered for therapeutic purposes, (b) any diagnostic assay methodology that is not an RIA Product, and (c) the right to market, offer for sale,
or knowingly permit the distribution of any RIA Product in the United States of America. In any country within Territory C, Shionogi nay grant only one (1) sublicense or distributorship under the rights granted in this Section 3.3; provided that (a)
such sublicense or distributorship and any further sublicense or distributorship granted thereunder allow only a single entity to market or sell RIA Products in such a country and (b) Shionogi itself does not also simultaneously market or sell a RIA
Product in that country. 
  
 3.4    Other Licenses.    Shionogi
acknowledges that Scios has granted similar licenses to Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064-3500, U.S.A. and Biosite Diagnostics Inc., 11030 Roselle Street, San Diego, California 92121, U.S.A. (collectively the
“Scios Diagnostic Licensees”) for Territory A and that these companies or their successors or sublicensees may simultaneously market Diagnostic Products in Territory A. 
  
 ARTICLE IV. 
 RIGHTS GRANTED BY SHIONOGI 
  
 4.1    Grant for Diagnostic Products in Territory A.    Shionogi hereby grants to Scios,
subject to the terms and conditions set forth herein, the non-exclusive right and license under the Shionogi Patent Rights to make, have made, use, have used, import, have imported, export, have exported, offer for sale, sell and have sold any
Diagnostic Product within Territory A. Scios shall not grant any sublicense or distributorship as to any country of Territory A under the rights granted in this Section 4.1 without the prior consent of Shionogi; provided, however, that Scios may
grant such sublicense or distributorship to the Scios Diagnostic Licensees without the prior consent of Shionogi. If Scios wishes to grant any sublicense under the rights granted in this Section 4.1 to any third party other than the Scios Diagnostic
Licensees, then Scios shall advise Shionogi of such intent and Scios shall obtain Shionogi’s prior written consent, such consent not to be unreasonably withheld. Any sublicense under this Section 4.1 shall be consistent with the other
provisions of this Agreement. 
  
 4.2    Grant for Therapeutic Products in Territory
B.    Shionogi hereby grants to Scios, subject to the terms and conditions set forth herein, the exclusive right and license under the
 
 
 *****    Confidential portions of this material have been omitted and filed separately with the
Securities and Exchange Commission. 

 
 4 

 
 Confidential Treatment Requested 
 
 
Shionogi Patent Rights to make, have made, use, have used, import, have imported, export, have exported, offer for sale, sell and have sold any Therapeutic Product within Territory B. Scios may
grant any sublicense or distributorship as to any country of Territory B under the rights granted in this Section 4.2 without the prior consent of Shionogi. Any sublicense under this Section 4.2 shall be consistent with the other provisions of this
Agreement. 
  
 ARTICLE V. 
 ROYALTIES 
  
 5.1    Royalty for Diagnostic
Product.    No royalty shall be payable by Scios to Shionogi regarding the license granted under Section 4.1 or by Shionogi to Scios regarding the licenses granted under Section 3.1, Section 3.2 and Section 3.3. 

 
 5.2    Royalties for Therapeutic Product.    In consideration of the right and
license granted by Shionogi to Scios for Therapeutic Product under Section 4.2, Scios shall pay Shionogi a royalty equal to [*****] of the Net Sales of Therapeutic Product as long as at the time of sale one or more Valid Claims in an issued patent
included in the Shionogi Patent Rights exists in the country of sale. If at the time of sale of the Therapeutic Product no patent included in the Shionogi Patent Rights has issued in such country containing a Valid Claim, but one or more patent
applications that are included in the Shionogi Patent Rights and containing a Valid Claim is pending in such country at the time of sale, then such royalty rate shall be reduced to [*****] of Net Sales of Therapeutic Products. However, the duration
of Scios’ obligation to pay the reduced royalty [*****] shall not be for more than four (4) years after the first commercial sale of a Therapeutic Product in such country, determined on a country by country basis. If a Valid Claim within a
patent included in the Shionogi Patent Rights subsequently issues in any such country, Scios shall, from the date of issuance, pay the [*****] royalty on Net Sales of Therapeutic Product in such country for the remaining life of such Valid Claim in
that country. Even if Scios supplies either BNP in bulk form or Therapeutic Product to its Sublicensee(s), the royalty set forth in this Section 5.2 shall be paid on the Net Sales of Therapeutic Product made by such Sublicensee(s) that are covered
by a Valid Claim of a patent within the Shionogi Patent Rights existing in the country of sale at the time of sale. Sales of BNP in bulk form or of Therapeutic Product between or among Scios, its Affiliates and Sublicensee(s) shall not be subject to
running royalties under this Section 5.2. Running royalties shall only be calculated on Scios’, its Affiliate(s)’ or its Sublicensee(s)’ sale of the Therapeutic Product to a Third Party. The obligation to pay royalties to Shionogi
under this Section 5.2 is imposed only once with respect to the same unit of Therapeutic Product regardless of the number of Valid Claims within the Shionogi Patent Rights. There shall be no multiple royalties or minimum royalties associated with
this Agreement. 
  
 5.3    Term of Royalty Obligation.    Scios’
obligation to pay royalties on Therapeutic Products under Section 5.2 will expire, on a country-by-country basis, on the date when the last Valid Claim within the Shionogi Patent Rights in the country of sale expires, lapses or is invalidated.

  
 5.4    Payments by Scios.    Royalties accruing to Shionogi
pursuant to Section 5.2 shall be calculated [*****]. Scios shall pay the royalties under Section 5.2 in conjunction with the
 
 
 *****    Confidential portions of this material have been omitted and filed separately with the
Securities and Exchange Commission. 

 
 5 

 
 Confidential Treatment Requested 
 
 
delivery of a written report to Shionogi [*****] which shows, with respect to each country and each Therapeutic Product, the volume and Net Sales of the Therapeutic Product. 

 
 5.5    Place of Payment; Currency Conversion.    All royalty payments due
Shionogi shall be payable in United States dollars to the following bank account of Shionogi or such other account as may be designated by Shionogi from time to time. In the case of sales made by Sublicensee(s) of Scios, the amounts payable to
Shionogi as a royalty hereunder for sales of Therapeutic Product covered by a Valid Claim within the Shionogi Patent Rights in a currency other than United States dollars shall be as determined under the agreement between Scios and its Sublicensee.
In the case of sales made directly by Scios and its Affiliates, the amounts payable to Shionogi as a royalty hereunder for sales of Therapeutic Product covered by a Valid Claim within the Shionogi Patent Rights in a currency other than United States
dollars shall be determined by converting the total royalty on Net Sales for a calendar quarter (computed in the currency in which the sales were made) directly into United States dollars using the closing spot exchange rate between the two
currencies quoted in the Wall Street Journal on the last business day of the applicable calendar quarter. If direct conversion from a currency other than United States dollars to United States dollars is not practically feasible, the parties shall
negotiate in good faith other conversion mechanism. 
  
 
	 BANK ACCOUNT
 
	 
	 Bank Name:
 Bank Address:
 Account Name:
 Account No.:
 	  	 The Sumitomo Bank, Ltd., Head Office
 6-5, Kitahama 4-chome, Chuo-ku, Osaka,
Japan
 Shionogi & Co., Ltd.
 230834
 

 
  
 5.6    Taxation of
Royalties.    Insofar as any royalties which are due Shionogi under this Agreement are subject to taxation where the taxes are imposed upon Shionogi, Shionogi agrees to bear such taxes. Shionogi hereby authorizes Scios to
withhold such taxes from the payments which are payable to Shionogi in accordance with this Agreement if Scios is either required to do so under the tax laws of the country of sale or the United States of America or directed to do so by an agency of
either such government. Scios shall furnish Shionogi with the best available evidence of payment whenever Scios deducts such tax from any payments due Shionogi without delay. 
  
 ARTICLE VI. 
 REPORTS 
  
 With each [*****] payment made under Section 5.2, Scios shall deliver a summary of all Net Sales for [*****]. Each such report shall include at least the following
information: (a) gross receipts from sales of Therapeutic Products for which a royalty is payable under Section 5.2; (b) any deductions from gross receipts used to arrive at Net Sales; and (c) Scios’ computation of the aggregate earned
royalties payable to Shionogi. 
 
 *****    Confidential portions of this material have been omitted and filed separately with the Securities and
Exchange Commission. 

 
 6 

 
 Confidential Treatment Requested 
 
  
 ARTICLE VII. 
 RECORDS and AUDITS 
  
 7.1    Records.    Scios shall keep full and accurate accounting records containing all particulars that may be necessary for
the purpose of calculating all royalties accrued to Shionogi under Section 5.2. Such records, together with all necessary supporting data, shall be kept at Scios’ Head Office. All such records shall be open for inspection at Shionogi’s
cost on a confidential basis at all reasonable times by an internationally recognized accounting firm designated by Shionogi for the purpose of verifying quarterly sales reports and compliance with this Agreement and providing to Shionogi the
conclusions it has reached in such analysis but not the specific sales figures achieved by Scios or its Affiliates and Sublicensees. An adjusting payment shall be made upon demonstration of any underpayment. Such an inspection may occur no more
frequently than once in each two calendar years. 
  
 7.2    Expense of
Audit.    The fees and expenses of the accounting firm designated by Shionogi to perform an examination pursuant to Article 7.1 shall be borne by Shionogi; provided, however, that if any audit shall show that Scios underpaid
the royalties due to Shionogi under this Agreement as to the period being audited by more than three percent (3%) of the amount that was payable for such period, then Scios shall, in addition to immediately paying to Shionogi any such deficiency,
immediately reimburse Shionogi for the cost of such audit. 
  
 7.3    Retention.    Books and records required to be maintained by Scios hereunder shall be preserved for at least four (4) years from the date of the royalty payment to which they
pertain. 
  
 ARTICLE VIII. 
 PATENTS 
  
 8.1    Status Reports.    Scios
shall notify Shionogi of any change in status of patents and/or patent applications listed in Appendix A and of the filing of any patent applications within the scope of the Scios Patent Rights and Appendix A shall be amended by Scios from time to
time to reflect such changes. Shionogi shall notify Scios of any change in status of patents and/or patent applications listed in Appendix B and of the filing of any patent applications within the scope of the Shionogi Patent Rights and Appendix B
shall be amended by Shionogi from time to time to reflect such changes in order that Scios may calculate the royalties payable under Section 5.2. In Japan, the European Union and all other countries that have patent term extension laws which allow
the life of a patent to be extended as to specific product to compensate for patent protection lost during the regulatory process, if requested by the Licensee, the Patent Owner shall cooperate and make necessary filings to extend the term of the
Patent Owner’s patents as they apply to any product of the Licensee. The parties agree that the preceding sentence shall not apply as to patents issued in the United States so that each party is free to select the United States patent that it
wishes to extend as to its own products. 
  
 8.2    Patent Matters in the United States of
America.    Shionogi shall be free to secure, maintain, defend and enforce at its own cost any of the patents and patent applications included within the Shionogi Patent Rights in the United States of America in such manner
as .Shionogi may elect after reasonable consideration of the views of Scios and Scios’ Sublicensees. Shionogi
 
 
 *****    Confidential portions of this material have been omitted and filed separately with the
Securities and Exchange Commission. 

 
 7 

 
 Confidential Treatment Requested 
 
 
shall have complete discretion with regard to strategy to be employed in the prosecution of the Shionogi Patent Rights in the United States of America, including the right to abandon any claims
or applications. Scios shall be free to secure, maintain, defend and enforce any of the patents and patent applications included within the Scios Patent Rights in the United States of America in such manner as Scios may elect after reasonable
consideration of the views of Shionogi and Shionogi’s Sublicensees. Neither party shall be obligated to defend claims brought against the other party by any Third Party claiming that a patent right of the Third Party is being infringed in the
United States of America. Similarly, each party shall be free to enforce the patents issued to it, in such a manner as it elects, against any Third Party infringing such patents. 
  
 8.2.1    Patent Marking in the United States of America.    Licensee and its Sublicensees shall make
reasonable best efforts to mark all products it makes, uses or sells in the United States of America or their containers, as consistent with the patent marking laws of the United States of America. 
  
 8.3    Patent Matters in Japan.    The Patent Owner shall have complete discretion with
regard to strategy to be employed in the prosecution of its own Patent Rights in Japan, including the right to abandon any claims or applications. 
  
 8.3.1    Patent Rights Maintenance in Japan.    The Patent Owner shall prosecute at its own cost its own
Patent Rights in Japan. The Patent Owner shall bear any Japanese renewal fees for its own Patent Rights. The Patent Owner may give to the Licensee three (3) months notice that the Patent Owner does not intend to continue the payment of any renewal
fee in Japan for a licensed patent, in which event the Licensee shall have the right to make such Japanese renewal fee payments directly and to have such licensed patent assigned to Licensee as to Japan. 
  
 8.3.2    Defense of Patent Infringement Suits in Japan.    In the event any
claim is made against licensee or any Sublicensee during the term of this Agreement alleging that the manufacture, use or sale of a Diagnostic Product or a Therapeutic Product (as the case may be) in Japan infringes any patent of a Third Party,
Licensee shall promptly notify the Patent Owner in writing. Licensee shall assume the primary responsibility for the conduct of the defense of any such suit in Japan and shall indemnify and hold the Patent Owner harmless against any damages, costs,
fees and expenses resulting from any such claim. Upon the reasonable request of Licensee, the Patent Owner shall assist Licensee and shall cooperate in any such litigation. The Patent Owner may participate in the litigation at its sole discretion
and at its own cost. 
  
 8.3.3    Suits for Third Party Infringement in
Japan.    In the event Licensee or the Patent Owner becomes aware of any infringement in Japan of any patent right licensed under this Agreement, that party shall promptly notify the other party in writing. The Patent Owner
shall have the first right to bring, at the Patent Owner’s own expense, an action relating to the infringement of the patent rights owned by the Patent Owner against any Third Party, and Licensee shall have no rights to any recovery under such
suit unless it shall, at its own expense, join the suit and prove its own damages. If the Patent Owner does not bring a patent infringement action within six (6) months from the date of notification by Licensee of an alleged infringement, and if
Licensee is materially and adversely affected by such infringement, Licensee, after notifying the Patent Owner in writing, shall be entitled to bring such infringement action at Licensee’s own expense. The award or settlement in such litigation
brought by Licensee shall
 
 
 *****    Confidential portions of this material have been omitted and filed separately with the
Securities and Exchange Commission. 

 
 8 

 
 Confidential Treatment Requested 
 
 
first be used to pay the reasonable litigation costs of Licensee’s suit. If Licensee’s recovery exceeds its litigation costs (including reasonable attorneys fees), Licensee shall pay to
the Patent Owner from the remaining recovery an amount equal to the amount that would have been payable to the Patent Owner as a royalty if the infringing sales had been made by Licensee, its Affiliates or its Sublicensees. The Licensee may retain
any recovered amount remaining after any required payment to the Patent Owner. 
  
 8.3.4    Defense of Patent Rights in Japan.    In the event that the Patent Owner becomes aware of any legal action or proceeding brought by any Third Party for the purpose of
invalidating or preventing the issuance of any patent within the Patent Rights, including any opposition proceeding and any legal action seeding a declaratory judgment of invalidity, the Patent Owner shall promptly notify Licensee in writing. The
Patent Owner shall have the right, at its own expense, to conduct the defense in any such action. If the Patent Owner chooses not to defend against such action, then Licensee may, at its own expense, defend against such action. 

 
 8.4    Patent Rights in Other Countries. 
  
 8.4.1    Patent Marking.    Licensee shall make reasonable best efforts to mark all products offered for
sale, sold, or distributed in countries other than Japan and the United States of America (the “Row Countries”) under the terms of this agreement, or their containers, as consistent with the patent marking laws of the country of sale.

  
 8.4.2    Patent Rights Maintenance in Row
Countries.    In the Row Countries, the Patent Owner shall prosecute and maintain, as it elects and at its own cost, its own patent rights, including the defense of any opposition proceedings or interferences. The Patent
Owner shall have complete discretion with regard to strategy to be employed in the prosecution of the patent rights that it owns, including the right to abandon any claims or applications. 
  
 8.4.3    Suits for Third Party Infringement in Row Countries.    In the event Licensee or the Patent Owner
becomes aware of any infringement in Row Countries of any Patent Right licensed under this Agreement, that party shall promptly notify the other party in writing. The Patent Owner shall have the first right to bring, at the Patent Owner’s own
expense, an action relating to the infringement of the patent rights owned by the Patent Owner against any Third Party, and Licensee shall have no rights to any recovery under such suit unless it shall, at its own expense, join the suit and prove
its own damages. If the Patent Owner does not bring a patent infringement action within six (6) months from the date of notification by Licensee of an alleged infringement, and if Licensee is materially and adversely affected by such infringement,
Licensee, after notifying the Patent Owner in writing, shall be entitled to bring such infringement action at Licensee’s own expense. The award or settlement in such litigation brought by Licensee shall first be used to pay the reasonable
litigation costs of Licensee’s suit. If Licensee’s recovery exceeds its litigation costs (including reasonable attorneys fees), Licensee shall pay to the Patent Owner from the remaining recovery an amount equal to the amount that would
have been payable to the Patent Owner as a royalty if the infringing sales had been made by Licensee, its Affiliates or its Sublicensees. The Licensee may retain any recovered amount remaining after any required payment to the Patent Owner.

 
 *****    Confidential portions of this material have been omitted and filed separately with the Securities and Exchange Commission. 

 
 9 

 
 Confidential Treatment Requested 
 
  
 8.4.4    Defense of Patent Infringement Suits in Row Countries.    In the event any claim is made against
Licensee, its Sublicensees, agents, distributors or re-sellers in the Row Countries during the term of this Agreement alleging that the manufacture, use or sale of a product under a license granted by this Agreement infringes any patent of a Third
Party, Licensee shall promptly notify the Patent Owner in writing. Licensee shall assume the primary responsibility for the conduct of the defense of any such suit and shall indemnify and hold the Patent Owner harmless against any damages, costs,
fees and expenses resulting from any such claim. Upon the reasonable request of Licensee, the Patent Owner shall assist Licensee and shall cooperate in any such litigation. 
  
 ARTICLE IX. 
 TERM 
  
 9.1    Term:    This Agreement shall be in full force and effect from the Effective Date and, unless otherwise terminated by
operation of law or by acts of the parties in accordance with the terms of this Agreement, shall remain in effect until the expiration of the last patent within the Scios Patent Rights or the Shionogi Patent Rights. 
  
 9.2    Obligations that Survive Expiration.    Obligations that will survive the expiration
of this Agreement include: Articles 1, 2, 7, 10, 11 and 12, and Sections 9.2, 13.1, 13.3, 13.8 and 13.10. 
  
 ARTICLE X.

 WARRANTIES AND DISCLAIMERS 
  
 10.1    Right to License.    Shionogi hereby represents and warrants that it is the owner of the entire right, title and interest in the Shionogi Patent Rights, and is entitled to grant
the rights and licenses specified in Article 4 to Scios. 
  
 10.2    Right to
License.    Scios hereby represents and warrants that it is the owner of the entire right, title and interest in the Scios Patent Rights, and is entitled to grant the rights and licenses specified in Article 3 to Shionogi.

  
 10.3    Non-Assertion Clause.    Shionogi agrees that it will not
assert any patent that is not included in the Shionogi Patent Rights covering any BNP or its intermediate (including DNA and expression vectors) or methods used in the manufacture of BNP which Shionogi owns or controls against Scios or its
Affiliates or its Sublicensees based on Scios’ or its Affiliates’ or its Sublicensees’ manufacture, use or sale of the Therapeutic Products as permitted under this Agreement so long as Scios is in material compliance with the terms of
this Agreement; provided, however, that this non-assertion agreement shall not prevent Shionogi from asserting against Scios or its Affiliates or Sublicensees any patent relating to a novel method of formulating BNP in a Therapeutic Product. Scios
agrees that it will not assert any patent that is not included in the Scios Patent Rights covering any BNP or its intermediate (including DNA and expression vectors) or methods used in the manufacture of BNP which Scios owns or controls against
Shionogi or its Affiliates or its Sublicensees based on Shionogi’ or its Affiliates’ or its Sublicensees’ manufacture, use or sale of the Diagnostic Products as permitted under this Agreement so long as Shionogi is in material
compliance with the terms of this Agreement;
 
 
 *****    Confidential portions of this material have been omitted and filed separately with the
Securities and Exchange Commission. 

 
 10 

 
 Confidential Treatment Requested 
 
 
provided, however, that this non-assertion agreement shall not prevent Scios from asserting against Shionogi or its Affiliates or Sublicensees any patent relating to a novel method of formulating
BNP in a Diagnostic Product. 
  
 10.4    No Contest.    If either of
the parties, either directly or indirectly through a straw man or other entity or person that the party has the power to control, either contests the validity of any patent or patent application within the scope of Patent Rights of the other party
or takes any action to make any patent or patent application within the scope of Patent Rights of the other party invalid or unenforceable, such other party may terminate the rights and licenses that it has granted under this Agreement to the party
who contests or takes action as described above in this Section 10.4, such termination to be effective upon thirty (30) days prior written notice. Notwithstanding the giving of such termination notice, the party giving the termination notice shall
retain all rights and licenses granted to it by the other party under this Agreement. 
  
 10.5    Exclusion by Both Parties.     EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, THE PARTIES EXPRESSLY DISCLAIM ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT
LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT. 
  
 10.6    Product Liability Disclaimer.    All warranties in connection with a Diagnostic Product and/or Therapeutic Product shall be made by the party selling such product and shall not
directly or by implication obligate the other party or any of its officers, employees or agents. 
  
 ARTICLE XI.

 INDEMNITY 
  
 Each
party (the “Selling Party”) hereby agrees to indemnify, hold harmless and defend the other party (the “Non Selling Party”), its officers, employees and agents, against any and all claims, suits, losses, damage, costs, fees and
expenses of any type, made or suffered by any third party, resulting from or arising out of the exercise of any license granted under this Agreement, including, without limitation: 
  
 (a)    The manufacture, packaging, use, sale, or other distribution of a Diagnostic Product and/or Therapeutic Product by the Selling
Party, its Affiliates and/or Sublicensees; or 
  
 (b)    Any representation made
or warranty expressly or impliedly given by the Selling Party with respect to any Diagnostic Product and/or Therapeutic Product. 
  
 HOWEVER, UNDER NO CIRCUMSTANCES SHALL THE SELLING PARTY BE LIABLE TO THE NON SELLING PARTY UNDER THIS ARTICLE 11 TO THE EXTENT SUCH CLAIMS, SUITS, LOSSES, DAMAGES, COSTS, FEES AND EXPENSES RESULT FROM OR ARISE OUT OF THE
NEGLIGENCE OR WILLFUL MISCONDUCT OF THE NON SELLING PARTY. 
 
 *****    Confidential portions of this material have been omitted and filed
separately with the Securities and Exchange Commission. 

 
 11 

 
 Confidential Treatment Requested 
 
  
 ARTICLE XII. 
 CONFIDENTIALITY 
  
 12.1    Except as expressly permitted herein, during the term of this Agreement and for a period of [*****] after the expiration of this Agreement,
Shionogi and Scios shall keep all information received from the other party (including the information received under the Terminated Agreements) strictly confidential and shall not disclose the same to any Third Parties without the prior written
consent of the other party, except such information which: 
  
 (i)    is or
becomes publicly known through no fault of the receiving party, 
  
 (ii)    is
already known to the receiving party prior to disclosure by the disclosing party as evidenced by the business records of the receiving party, 
  
 (iii)    is learned by the receiving party from a Third Party entitled to disclose it, 
  
 (iv)    is required to be disclosed in order to comply with a court order, law or regulation, or required by a competent authority to
commercialize the licensed Diagnostic Products and/or licensed Therapeutic Products, or 
  
 (v)    is independently developed by the receiving party without the use of or reference to such information as evidenced by the business records of the receiving party. 
  
 12.2    The Parties undertake to keep secret and confidential and to withhold from the Third Party, to the extent
legally possible, the terms and conditions of this Agreement and the Terminated Agreements. The obligations under this Section 12.2 shall also survive expiration of this Agreement for a period of [*****] years following such expiration.

  
 ARTICLE XIII. 
 MISCELLANEOUS 
  
 13.1    Waiver.    No waiver
by either party hereof of any breach or default of any of the covenants or agreements herein set forth shall be deemed a waiver as to any subsequent or similar breach or default. 
  
 13.2    Notices.    Any notice or other communication required or permitted to be given to either party hereto shall be in
writing and shall be deemed to have been properly given and to be effective on the date of delivery if delivered in person or by facsimile (later confirmed by mail) or ten (10) days after mailing by registered or certified mail, postage paid, to the
other party at the following address: 
  
 
	 In the case of Shionogi:
 	  	 Shionogi & Co., Ltd.
 12-4, Sagisu 5-chome
 Fukushima-ku
 Osaka 553-0002, Japan
 Attention: General
Manager,
 Intellectual Property Department
 Facsimile: +81-6-6458-3702
 

 
 
 *****    Confidential portions of this material have been omitted and filed separately with the
Securities and Exchange Commission. 

 
 12 

 
 Confidential Treatment Requested 
 
  
 
	 In the case of Scios:
 	  	 Scios Inc.
 749 North Mary Ave.
 Sunnyvale, CA 94085 USA
 Attention: General Counsel
 Facsimile: (408)
616-8319
 

 
  
 Either party may change its address or facsimile number for
communications by a notice to the other party in accordance with this Article 13.2. 
  
 13.3    Governing Law and Arbitration.    This Agreement shall be interpreted and construed in accordance with the laws of New York without reference to the rules of conflict of laws;
provided, however, all questions concerning the construction or scope of the Patent Rights shall be decided in accordance with the patent laws of the country of issue. The parties hereto shall use their best efforts to settle amicably any
controversies arising out of this Agreement. Any controversy or disputes or claims arising between the parties in connection with this Agreement which cannot be settled in an amicable way shall be finally settled under the Rules of Arbitration of
the International Chamber of Commerce, by one or more arbitrators appointed in accordance with the said Rules. Proceedings shall be conducted in the English language. Any award or decision made in such arbitration shall be final. and binding upon
the parties and enforceable in a court of competent jurisdiction. The arbitration shall be held in San Francisco, California, the United States of America if such proceedings are requested by Shionogi, or Osaka, Japan if such proceedings are
requested by Scios. 
  
 13.4    Headings.    The headings of the
several sections are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. 
  
 13.5    Amendment.    No amendment or modification hereof shall be valid or binding upon the parties unless made in writing
and signed by both parties. 
  
 13.6    Force Majeure.    Any delay in
performance by any party under this Agreement shall not be considered a breach of this Agreement if and to the extent caused by occurrences beyond the reasonable control of the party affected, including but not limited to acts of God, embargoes,
governmental restrictions, strikes or other concerted acts of workers, fire, flood, explosion, riots, wars, civil disorder, rebellion or sabotage. The party suffering such occurrence shall immediately notify the other party and the time for
performance of any obligation hereunder shall be extended by the actual time of delay caused by the occurrence. 
  
 13.7    Independent Contractors.    In making and performing this Agreement, Shionogi and Scios act and shall act at all times as independent contractors and nothing contained in this
Agreement shall be construed or implied to create an agency, partnership or employer and employee relationship between Shionogi and Scios. At no time shall one party make commitments or incur any charges or expenses for or in the name of the other
party except as specifically provided herein. 
 
 *****    Confidential portions of this material have been omitted and filed separately with the
Securities and Exchange Commission. 

 
 13 

 
 Confidential Treatment Requested 
 
  
 13.8    Severability.    If any term, condition or provision of this Agreement is held to be unenforceable for any reasons,
it shall if possible, be interpreted rather than voided, in order to achieve the intent of the parties to this Agreement to the extent possible. In any event, all other terms, conditions and provisions of this Agreement shall remain valid and
enforceable to the full extent. 
  
 13.9    Additional
Documents.    Each party agrees to execute such further papers or agreements as may be necessary to effect the purpose of this Agreement. 
  
 13.10    Assignment.    This Agreement shall not be assigned by either party without the prior written consent of the other party, except as part of a
sale or transfer, by way of merger or otherwise, of all or substantially all of the business assets of such party to which this Agreement relates, or by assignment to an Affiliate and provided further that the assignee agrees to be bound in writing
by all the terms of this Agreement in place of the assignor, or the assignor agrees to remain responsible for the obligations of the assignee pursuant to the terms set forth herein. 
  
 13.11    Trade Names and Trademarks.    Nothing contained in this Agreement shall be construed as conferring any right of one
party to use in advertising, publicity, or other promotional activities, any names, trade name, trademark, or other designation of the other party without such other party’s prior written consent and approval. Each party hereto further agrees
not to use or refer to this Agreement or the license granted hereunder in any promotional activity associated with the licensed Diagnostic Products and/or Therapeutic Products without the express written approval of the other party. 

 
 13.12    Entire Agreement.    This Agreement embodies the entire understanding
of the parties and shall supersede all previous communications, representations or understandings, either oral or written, between the parties relating to the subject matter hereof. 
  
 IN WITNESS WHEREOF, both Shionogi and Scios have executed this Agreement, in duplicate originals, by their respective duly authorized officers, as of the Effective Date.

  
 
	 SHIONOGI & CO., LTD.
 	 	  	 	 SCIOS INC.
 
	 
	 By:
 	 	 /S/    REIJI TAKEDA,
PH.D.        
 	 	  	 	 By:
 	 	 /S/    RICHARD B. BREWER        
 
	  	 	 
	 	  	 	  	 	 

	 
	 Name:
 	 	 Reiji Takeda, Ph.D.
 	 	  	 	 Name:
 	 	 Richard B. Brewer
 
	  	 	 
	 	  	 	  	 	 

	 
	 Title:
 	 	 Director International Business Division
 	 	  	 	 Title:
 	 	 President and CEO
 
	  	 	 
	 	  	 	  	 	 

	 
	 Date:
 	 	 October 10, 2000
 	 	  	 	 Date:
 	 	 October 19, 2000
 
	  	 	 
	 	  	 	  	 	 

 
  
 Attachments: 
  
 Appendix A    Scios Patent Rights 
  
 Appendix
B    Shionogi Patent Rights 
 
 *****    Confidential portions of this material have been omitted and filed separately with the
Securities and Exchange Commission. 

 
 14 

 
 Confidential Treatment Requested 
 
  
 APPENDIX A 
 SCIOS PATENT RIGHTS 
 (as of March 16, 2000) 
  
 [*****] 
 
 *****    Confidential portions of this material have been omitted and filed separately with the Securities and Exchange Commission. 

 
 15 

 
 Confidential Treatment Requested 
 
  
 APPENDIX B 
 SHIONOGI PATENT RIGHTS 
 (as of March 16, 2000) 
  
 [*****] 
 
 *****    Confidential portions of this material have been omitted and filed separately with the Securities and Exchange Commission. 

 
 16 

 
 Confidential Treatment Requested 
 
  
 [Scios Letterhead] 
  
 March 5, 2002 
  

Mr. Yuzo Tanaka 
 General Business Manager 
 International Business Division 
 Shionogi & Co. Ltd. 
 1-8, Doshomachi 3-chome

 Chuo-ku, Osaka 541-0045 
  
 Dear Mr. Tanaka: 

 

	Re:
	 
	Modification of May 13, 1998 Scios/Shionogi Cross-License License Agreement 
 

  

Scios and Shionogi hereby agree, that the above-referenced Cross-License Agreement shall be modified, effective upon execution of this letter, in the following respects: 

 
 Section 3.2 shall be amended as follows: 
  

	3.2
	 
	Grant for Diagnostic Products in Territory A. Scios hereby grants to Shionogi, subject to the terms and conditions set forth herein, the semi-exclusive
right and license under the Scios Patent Rights to make, have made, use, have used, import, have imported, export, have exported, offer for sale, sell and have sold any Diagnostic Product in Territory A. Scios reserves the right to grant in
Territory A, additional licenses under the Scios Patent Rights; provided, however, that Scios agrees that [*****], shall be authorized under licenses granted by Scios under the Scios Patent Rights within Territory A to make, have made, use, have
used, import, have imported, export, have exported, offer for sale, sell, and have sold Diagnostic Products in any country of Territory A. In any country within Territory A, Shionogi may grant only one (1) sublicense under the rights granted in this
Section 3.2 pursuant to which the sublicensee’s rights hereunder shall include the right to use one or more distributors to market or sell Diagnostic Products; provided that (a) such sublicense and any further sublicense granted thereunder
allow only a single entity to market or sell Diagnostic Products in such a country with such entity having the right to use one or more distributors; and (b) Shionogi itself does not also simultaneously market or sell a Diagnostic Product in that
country. 
 

  
 The parties agree that this Modification Letter may be executed via facsimile
signature. If the foregoing is acceptable please sign and return a fully executed original to the undersigned at the above address. 
  

	Agreed
	 
	and Accepted: 
 

  
 
	 SCIOS INC.
 	 	  	 	 SHIONOGI & CO., LTD.
 
	 
	 By:
 	 	 /S/    MATTHEW R. HOOPER        
 	 	  	 	 By:
 	 	 /S/    REIJI TAKEDA,
PH.D.        
 
	  	 	 
	 	  	 	  	 	 

	  	 	 Matthew R. Hooper
 	 	  	 	  	 	 Reiji Takeda, Ph.D.
 
	 
	 Title:
 	 	 Vice President & General Counsel
 	 	  	 	 Title:
 	 	 Director and General Manager
 
	  	 	 
	 	  	 	  	 	 

	  	 	  	 	  	 	  	 	 International Business Division
 
	 
	 Date:
 	 	 March 28, 2002
 	 	  	 	 Date:
 	 	 March 28, 2002
 
	  	 	 
	 	  	 	  	 	 

 
 
 *****    Confidential portions of this material have been omitted and filed separately with the
Securities and Exchange Commission. 

 
 17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00046-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00046-of-00352.parquet"}]]